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Background: Optimal surgical intervention for low-grade haemorrhoids is unknown. Rubber band ligation
(RBL) is probably the most common intervention. Haemorrhoidal artery ligation (HAL) is a novel alternative
that may be more efficacious.
Objective: The comparison of HAL with RBL for the treatment of grade II/III haemorrhoids.
Design: A multicentre, parallel-group randomised controlled trial.
Perspective: UK NHS and Personal Social Services.
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Setting: 17 NHS Trusts.
Participants: Patients aged ≥ 18 years presenting with grade II/III (second- and third-degree)
haemorrhoids, including those who have undergone previous RBL.
Interventions: HAL with Doppler probe compared with RBL.
Outcomes: Primary outcome – recurrence at 1 year post procedure; secondary outcomes – recurrence at
6 weeks; haemorrhoid severity score; European Quality of Life-5 Dimensions, 5-level version (EQ-5D-5L);
Vaizey incontinence score; pain assessment; complications; and cost-effectiveness.
Results: A total of 370 participants entered the trial. At 1 year post procedure, 30% of the HAL group had
evidence of recurrence compared with 49% after RBL [adjusted odds ratio (OR) = 2.23, 95% confidence
interval (CI) 1.42 to 3.51; p = 0.0005]. The main reason for the difference was the number of extra
procedures required to achieve improvement/cure. If a single HAL is compared with multiple RBLs then only
37.5% recurred in the RBL arm (adjusted OR 1.35, 95% CI 0.85 to 2.15; p = 0.20). Persistence of significant
symptoms at 6 weeks was lower in both arms than at 1 year (9% HAL and 29% RBL), suggesting significant
deterioration in both groups over the year. Symptom score, EQ-5D-5L and Vaizey score improved in both
groups compared with baseline, but there was no difference between interventions. Pain was less severe
and of shorter duration in the RBL group; most of the HAL group who had pain had mild to moderate pain,
resolving by 3 weeks. Complications were low frequency and not significantly different between groups.
It appeared that HAL was not cost-effective compared with RBL. In the base-case analysis, the difference
in mean total costs was £1027 higher for HAL. Quality-adjusted life-years (QALYs) were higher for HAL;
however, the difference was very small (0.01) resulting in an incremental cost-effectiveness ratio of £104,427
per additional QALY.
Conclusions: At 1 year, although HAL resulted in fewer recurrences, recurrence was similar to repeat RBL.
Symptom scores, complications, EQ-5D-5L and continence score were no different, and patients had more
pain in the early postoperative period after HAL. HAL is more expensive and unlikely to be cost-effective in
terms of incremental cost per QALY.
Limitations: Blinding of participants and site staff was not possible.
Future work: The incidence of recurrence may continue to increase with time. Further follow-up would
add to the evidence regarding long-term clinical effectiveness and cost-effectiveness. The polysymptomatic
nature of haemorrhoidal disease requires a validated scoring system, and the data from this trial will allow
further assessment of validity of such a system. These data add to the literature regarding treatment of
grade II/III haemorrhoids. The results dovetail with results from the eTHoS study [Watson AJM, Hudson J,
Wood J, Kilonzo M, Brown SR, McDonald A, et al. Comparison of stapled haemorrhoidopexy with
traditional excisional surgery for haemorrhoidal disease (eTHoS): a pragmatic, multicentre, randomised
controlled trial. Lancet 2016, in press.] comparing stapled haemorrhoidectomy with excisional
haemorrhoidectomy. Combined results will allow expansion of analysis, allowing surgeons to tailor their
treatment options to individual patients.
Trial registration: Current Controlled Trials ISRCTN41394716.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 20, No. 88. See the NIHR Journals Library website
for further project information.
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Plain English summary
Background
There are many treatments for piles (haemorrhoids). In less-severe cases, one treatment is rubber band
ligation (RBL), which involves placing a small band around the base of the pile to cut off the blood supply.
RBL is a relatively painless outpatient treatment with minimal complications but recurrence is common.
Haemorrhoidal artery ligation (HAL) uses a device to locate the arteries feeding the piles, which are then
stitched. This procedure takes longer and is more painful but may reduce recurrence. We compared these
two procedures to see which was best.
Results
One year after surgery, 49% of the patients had a recurrence of symptoms after RBL compared with 30%
of patients undergoing HAL. About one-third of RBL patients, whose symptoms persisted, underwent a
further surgical procedure, many having repeated RBL. If patients having further RBL are considered as
having a ‘course’ of therapy then there was minimal difference between the treatments. Most patients
initially felt better after surgery, but symptoms returned within the year. Symptom scores, quality of life,
continence and complications were similar after both procedures. Those undergoing HAL tended to have
more pain but the discomfort was not severe in the majority of patients and resolved by 1–3 weeks after
the operation. HAL is much more expensive.
Conclusion
Haemorrhoidal artery ligation reduced recurrence compared with RBL, but these RBL recurrences can often
be treated successfully by simple re-banding. A course of RBL, therefore, has similar recurrence rates to
HAL. HAL is also more painful in the short term, waiting time is longer and it is more expensive.
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Scientific summary
Background
Anal cushions are a normal component of the anal canal and are composed predominantly of vascular
tissue, supported by smooth muscle and connective tissue. Pathological changes in the anal cushions with
enlargement of the vascular plexus result in haemorrhoidal development. Haemorrhoids are common,
affecting as many as 1 in 3 of the population, and result in a significant burden to the UK NHS. Over
20,000 haemorrhoidal operations are carried out in England each year. Prevalence may be even higher in
professionally active people. Repeated visits to hospital for therapy represent a significant disruption to the
personal and working lives for this population in particular.
Treatment is dictated by the degree of symptoms and the degree of prolapse, and ranges from dietary
advice to rubber band ligation (RBL) in the outpatient department, to an operation under anaesthetic.
Although RBL is cheap, it has a high recurrence rate and often needs repeating. Failure may require
surgical intervention, commonly the traditional ‘open’ haemorrhoidectomy (OH) or a stapled
haemorrhoidopexy (SH), both requiring anaesthetic. OH is associated with considerable postoperative
discomfort and a delay in return to normal activity, but has a low recurrence rate. SH has a slightly higher
recurrence rate, but potentially shorter recovery. An alternative treatment is haemorrhoidal artery ligation
(HAL), which, although it also requires an anaesthetic, is thought to enable an even quicker return to
normal activity. Recurrence rates are reportedly similar to SH, but complication rates are lower.
There are substantial data in the literature concerning the efficacy and safety of RBL, including multiple
comparisons with other interventions. Recurrence varies from 11% to > 50%, the broad range probably
reflecting the definition of recurrence, severity of the disease, number of treatments and/or the intensity
and length of follow-up. In most studies, the incidence of recurrence is > 30% and appears greatest for
grade III (third-degree) haemorrhoids (prolapsing piles requiring manual reduction). Significant complications
are rare after RBL.
Although HAL requires an anaesthetic, evidence suggests a recovery that is similar to RBL, but an
effectiveness that approaches the more intensive surgical options. There are significant data about the
effectiveness of HAL, including four systematic reviews, 11 randomised controlled trials (RCTs), seven
non-randomised trials and > 60 case series. All of these reviews highlight the lack of good-quality data as
evidence for the advantages of the technique. There are no existing RCTs that compare HAL with RBL.
Objectives
The aim of this study was to establish the clinical effectiveness and cost-effectiveness of HAL compared
with conventional RBL in the treatment of people with symptomatic prolapsing haemorrhoids (second or
third degree).
The primary objective was to compare patient-reported symptom recurrence at 12 months following the
procedure. Recurrence was defined using a simple dichotomous outcome that was derived from a
previously published systematic review, and supplemented with general practitioner (GP) and hospital notes.
The secondary objectives were to compare postoperative:
l symptom severity score
l health-related quality of life [using the European Quality of Life-5 Dimensions (EQ-5D)]
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l continence (using the validated Vaizey incontinence score)
l pain [using a 10-cm visual analogue scale (VAS)]
l surgical complications
l need for further treatment
l clinical appearance of haemorrhoids at proctoscopy following recurrence
l health-care costs
l cost-effectiveness.
Methods
This was a multicentre, parallel-group RCT involving 18 centres throughout England and Scotland.
Delegated study staff located at individual centres identified and consented potential participants.
These participants fell into two basic groups:
1. Patients presenting to the surgical outpatient clinic (SOPC) with symptomatic haemorrhoids, for which
alternative diagnoses had been excluded either clinically or after investigation.
2. Patients with symptoms – due to haemorrhoids – confirmed, who returned to SOPC following one
unsuccessful RBL.
After consent, participants were individually randomised to HAL or RBL in equal proportion at all centres
using a web-based randomisation system.
Sheffield Clinical Trials Research Unit (CTRU) coordinated follow-up and data collection in collaboration
with the UK centres. Participant study data were collected and recorded on study-specific case report
forms and patient questionnaires, and then entered on to a web-based data capture system, transferring
data to Sheffield CTRU for analysis.
Data were collected to establish which patients had further treatment for recurrent symptoms or
complications following their initial procedure. This was achieved at a clinic visit around 6 weeks following
the intervention and by reviewing hospital records, asking the patients’ consultants, writing to patients’
GPs and questioning the patient via telephone interview at 12 months.
Setting
Sheffield Teaching Hospitals NHS Foundation Trust was the ‘clinical coordinating centre’ housing the Chief
Investigator. A further 17 centres screened patients and delivered the trial; one centre did not recruit, so
17 centres recruited participants. Recruitment took place in outpatient clinics, RBL took place in outpatient
clinics or theatre (depending on the Trust’s current practice) and HAL took place in theatre.
Participants
The target population was patients who were referred to collaborating centres for treatment of haemorrhoids.
Inclusion criteria
l Adults aged ≥ 18 years with symptomatic second- or third-degree (grade II/III) haemorrhoids.
SCIENTIFIC SUMMARY
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Exclusion criteria
l Patients who have had previous surgery for haemorrhoids (at any time).
l Patients who have had more than one injection treatment for haemorrhoids in the past 3 years.
l Patients who have had more than one RBL procedure in the past 3 years.
l Patients with known perianal sepsis, inflammatory bowel disease, colorectal malignancy or pre-existing
sphincter injury.
l Patients with an immunodeficiency.
l Patients who were unable to have general or spinal anaesthetic.
l Patients who were currently taking warfarin or clopidogrel bisulfate (clopidogrel) or who had any other
hypocoagulability condition.
l Patients who were currently taking nicorandil.
l Pregnant women.
l Patients who were unable to give full informed consent (this may be because of mental capacity or
language barriers).
l Patients who were previously randomised to this trial.
Sample size
We assumed that the proportion of patients who experience recurrence following RBL was 30% and
following HAL 15%. Therefore, the sample size required to detect a difference in recurrence rates with an
odds ratio (OR) of ‘2’, with 80% power and 5% significance, was 121 individuals per group. In order to
account for any between-surgeon variation and loss to follow-up, we increased this to 175 per group.
Interventions
The intervention was either RBL or HAL – both established and well-documented procedures, considered
as standard care by the National Institute for Health and Clinical Excellence.
Rubber band ligation is a basic surgical skill with which all senior staff are familiar and are competent
in performing.
Haemorrhoidal artery ligation is a simple procedure that uses existing surgical skills and has a short learning
curve. All of the surgeons involved in the study had completed the required training and, in addition, had
carried out the manufacturer’s recommendation of five procedures before commencing the study.
Statistical and health-economic analyses
Differences in the primary outcome of recurrence were analysed using logistic regression, adjusting for
gender, age and history of previous intervention as fixed effect covariates and surgeon as a random effect.
This allows the calculation of ORs with confidence intervals (CIs) for the effect of RBL relative to HAL,
adjusting for the effects of covariates and the clustering by surgeon. The secondary outcomes of pain,
symptoms and incontinence were analysed at each time point using a random-effects, generalised least
squares model, adjusting for the same covariates. Procedural complications and serious adverse events
(SAEs) were summarised as numbers and percentages.
A full economic evaluation, focusing on estimating the incremental cost per quality-adjusted life-year
(QALY) of HAL compared with RBL over the 12-month follow-up period, was also carried out. A secondary
cost-effectiveness analysis (CEA) was performed in terms of the incremental cost per recurrence avoided.
Long-term cost-effectiveness was estimated by extrapolating the analyses beyond the trial time horizon.
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Results
In total, 372 participants were randomly assigned to receive RBL or HAL; 187 patients were allocated to
receive RBL, and 185 were allocated to receive HAL. Two of these participants (both randomised to RBL)
were removed from the trial completely, as they were ineligible at the time of consent, and, therefore, a
total of 370 participants were entered into the trial. The recurrence rate for HAL was significantly lower
than for RBL at 12 months (30% vs. 49%, adjusted OR = 2.23, 95% CI 1.42 to 3.51; p = 0.0005). Further
treatment was required in 31% of the RBL group and 15% of the HAL group (adjusted OR for further
procedure = 2.86, 95% CI 1.65 to 4.93; p = 0.0002). Eighteen per cent of the RBL group received a
second banding session within the year. In these cases, because the initial haemorrhoids were incompletely
treated, excluding these RBLs as recurrence resulted in a larger reduction of our recurrence rate for RBL
and no statistical difference between the groups (HAL 30% vs. RBL 37.5%, adjusted OR 1.35, CI 0.85 to
2.15; p = 0.20).
At 6 weeks following the procedure, 13 (9%) of patients in the HAL group and 44 (29%) of patients in
the RBL group reported their haemorrhoidal symptoms as ‘unchanged’ or ‘worse’ (adjusted OR 4.35,
95% CI 2.19 to 8.65; p < 0.001).
The haemorrhoid symptom severity score improved in both arms compared with scores prior to procedure.
At 6 weeks, the mean scores reduced from 6.5 [standard deviation (SD) 3.3] to 4.0 (SD 3.5) for RBL and
from 6.4 (SD 3.0) to 3.0 (SD 3.1) for HAL. There was a statistically significant difference between groups at
6 weeks in favour of HAL (adjusted mean difference 1.0, 95% CI 0.3 to 1.8; p = 0.01) but no difference
was apparent at 1 year (difference in means 0.0, 95% CI –0.8 to 0.8; p = 0.98). Applying the definition
used by Nyström et al., in which a score of 0 or 1 points indicates symptomatic cure, the two interventions
were similar at both 6 weeks (HAL 38% vs. RBL 31%; adjusted OR 0.73, 95% CI 0.44 to 1.22; p = 0.23)
and 1 year (HAL 31% vs. RBL 27%; adjusted OR 0.79, 95% CI 0.46 to 1.38; p = 0.42) (Nyström PO,
Qvist N, Raahave D, Lindsey I, Mortensen N. Randomized clinical trial of symptom control after stapled
anopexy or diathermy excision for haemorrhoid prolapse. Br J Surg 2010;97:167–76).
Haemorrhoidal artery ligation was associated with a short-term reduction in mean health utility
(European Quality of Life-5 Dimensions, 5-level version) at 1 and 7 days postoperatively, whereas for RBL
the mean had reverted back at 1 week. The adjusted difference in means were 0.08 (95% CI 0.04 to 0.13;
p = 0.001) at 1 day and 0.08 (95% CI 0.05 to 0.12; p = 0.001) at 7 days in favour of RBL. The two arms
were similar (and above baseline values) at all time points from day 21 onwards.
There was a small reduction of about 1–2 points in the mean Vaizey faecal incontinence score 6 weeks
after both interventions. There was no evidence of a difference in incontinence score between the
two interventions. The majority of patients reported increased pain, measured by VAS, following both
procedures (56% RBL vs. 71% HAL). For RBL, this pain was usually of low intensity (median VAS score on
day 1: 3.0) and resolved rapidly to below baseline values (median VAS score on day 7: 1.0); about 50%
of patients required analgesics for the first few days after treatment. For HAL, the pain was significantly
greater, with moderate pain at day 1 (median VAS score 5.0, mean difference from RBL –1.2, 95% CI
–1.8 to –0.5; p < 0.001) and mild pain on day 7 post procedure (median VAS score 3.0, mean difference
from RBL –1.5, 95% CI –2.0 to –1.0; p < 0.001). Pain had resolved in almost all patients by the 3-week
assessment (median VAS score 0.0 RBL vs. 1.0 HAL, mean difference from RBL –0.1, 95% CI –0.6 to 0.3;
p = 0.44). Analgesia was required by the majority after a HAL procedure on a daily basis for the first week,
but tailed off such that at 3 weeks 72% of patients had stopped taking medication.
Twelve patients (7%) reported a SAE (in all cases entailing hospitalisation) following HAL procedure,
compared with two (1%) in the RBL arm. In the HAL arm there were six admissions due to pain, two
for urine retention, and one each of bleeding, wound infection, nausea/vomiting and a reaction to
anaesthetic. For RBL, both events related to prolonged hospitalisation: one for severe pain and one for
bleeding 12 days following banding.
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The main findings of within-trial cost–utility analysis suggest that HAL procedure appeared not to be
cost-effective compared with RBL at a cost-effectiveness threshold of £20,000–30,000 per QALY. In the
base-case results, the difference in mean total costs was £1027 higher for HAL than RBL. QALYs were higher
for HAL; however, the difference was very small (0.01), resulting in an incremental cost-effectiveness ratio
(ICER) of £104,427 per additional QALY. At the threshold of £20,000 per QALY, HAL has zero probability of
being cost-effective; at the threshold of £30,000, it has 0.05 probability of being cost-effective.
The base-case CEA suggests that the incremental cost per recurrence avoided was estimated as £4882.
In a sensitivity analysis scenario using recurrence from the consultant questionnaire only, the incremental
cost per recurrence was estimated as £6346. The extrapolation for 3 years beyond the trial time horizon
generated an ICER of £21,887 per QALY, and HAL has 0.34 probability of cost-effectiveness.
Conclusions
Haemorrhoidal artery ligation is a more clinically effective procedure than a single RBL intervention.
However, if HAL is compared with repeat RBL the procedures become equivalent in terms of recurrence.
Similarly, symptom severity score, complications, quality of life and continence score were no different
between interventions, and patients had more pain in the early postoperative period after a HAL
procedure. The HAL procedure is significantly more expensive than RBL and not cost-effective in terms of
cost per QALY.
Trial registration
This trial is registered as ISRCTN41394716 (UKCRN database ID 12486).
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Haemorrhoidal tissue, which forms the ‘anal cushions’, is a normal component of the anal canal and
is composed predominantly of vascular tissue, supported by smooth muscle and connective tissue.
Haemorrhoids result from enlargement of the haemorrhoidal plexus and pathological changes in the anal
cushions. They are common, affecting as many as 1 in 3 of the population.1
Approximately 23,000 haemorrhoidal operations were carried out in England in 2004–5,2 and the
prevalence may be even higher in professionally active people. Repeated visits to hospital for therapy
represent a significant disruption to the personal and working lives for this population in particular.
Treatment is dictated by the degree of symptoms and the degree of prolapse, and ranges from dietary
advice – to rubber band ligation (RBL) in the outpatient department – to an operation under general or
regional anaesthetic. Although RBL is cheap, it has a high recurrence rate, and patients often require
further visits to the outpatient department for repeat banding before exploring surgical options.3
Although there are some variations [such as LigaSure® (Covidien – Medtronic, Minneapolis, MN, USA)
haemorrhoidectomy], surgery is commonly traditional ‘open’ haemorrhoidectomy (OH) or a stapled
haemorrhoidopexy (SH); both require an anaesthetic. OH is associated with considerable postoperative
discomfort, sometimes necessitating an overnight hospital stay and a delay in return to normal activity, but
has a low recurrence rate; SH has a slightly higher recurrence rate, but is carried out as a day case and
patients return to normal activity more quickly.4 An alternative treatment is haemorrhoidal artery ligation
(HAL), which also requires an anaesthetic, but is thought to enable even quicker return to normal activity.
Recurrence rates are reportedly similar to SH, but complication rates are lower.5
There are substantial data in the literature concerning the efficacy and safety of RBL, including multiple
comparisons with other interventions.6–12 Recurrence varies from 11% to > 50%. This broad range
probably reflects the definition of recurrence (patient symptoms or clinical appearance), the grade of
haemorrhoids treated (grade I, no prolapse; grade II, spontaneously reducible prolapse; grade III, prolapse
requiring manual reduction; and grade IV, unreducible prolapse), the number of treatments and/or the
intensity and length of follow-up. In most studies, the incidence of recurrence is > 30% and appears
greatest for grade III haemorrhoids. Pain is common for a few hours following RBL and occasionally
patients experience pain so severe as to require admission to hospital (around 1%3), bleeding (3–4%,
sometimes necessitating further treatment9) and vasovagal symptoms (3%13). There have also been rare
incidences of blood transfusion3,11,14–18 and severe pelvic sepsis, with a few instances leading to death.13
Recurrences can be treated by re-banding or by surgical intervention.
Although HAL requires an anaesthetic, evidence suggests a recovery similar to RBL, but an effectiveness
that approaches the more intensive surgical options. The substantial data concerning effectiveness include
four systematic reviews,5,19–21 11 randomised controlled trials (RCTs),22–32 seven non-randomised trials33–39
and > 60 case series. An overview has been carried out by the National Institute for Health and Clinical
Excellence (NICE), which concludes that current evidence shows it to be a safe alternative to OH or SH;40
this is summarised below.
l In terms of efficacy, studies with > 1 year follow-up suggest bleeding, pain on defecation, and prolapse
(surrogates of recurrent symptoms) in 10%, 9% and 11% of patients, respectively.
l Regarding safety, postoperative haemorrhage requiring intervention (readmission, transfusion,
reoperation or correction of coagulopathy) was reported in < 1.2%, haemorrhoidal thrombosis was
seen in < 3.5% of patients and fissure formation in < 2.1%.
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l The data from the three RCTs comparing HAL with SH and OH are difficult to combine, but efficacy
seems similar for all of the procedures, with OH perhaps being superior in treating prolapse, although
it is unclear if a ‘pexy’ stitch was used in the HAL cases to reduce prolapse. OH appears to lead to
the most postoperative pain and longest recovery. There are conflicting results as to whether or not
the HAL technique results in less pain compared with SH. Complications were also more frequent
in the OH group, but occurred at a similar frequency when SH and HAL were used.
Rationale
Both of the systematic reviews and the NICE overview highlight the lack of good-quality data as evidence
for the advantages of the technique; most data are from case series. Even the numerous RCTs have
significant methodological drawbacks that make them subject to selection, performance, attrition and
detection bias. Indeed, none of the studies is powered to reach any meaningful conclusion. There are no
existing RCTs that compare HAL with RBL, although there is now one non-randomised comparison with
small numbers of patients.41
Research objectives
The HubBLe study aimed to establish the clinical effectiveness and cost-effectiveness of HAL compared
with conventional RBL in the treatment of people with symptomatic second- or third-degree (grade II or
grade III) haemorrhoids.
The primary objective was to compare patient-reported symptom recurrence at 12 months following
the procedure.
The secondary objectives were to compare postoperative:
l symptom severity score (adapted from Nyström et al.42)
l health-related quality of life [HRQoL; using the European Quality of Life-5 Dimensions (EQ-5D)43]
l continence (using the validated Vaizey incontinence score44)
l pain [using a 10-cm visual analogue scale (VAS)]
l surgical complications
l need for further treatment
l clinical appearance of haemorrhoids at proctoscopy following recurrence
l health-care costs
l cost-effectiveness.
Text reproduction
The findings of this trial have been published in The Lancet and as such there is reproduced text on
pp. 24–26 of The Lancet publication.45
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Chapter 2 Methods
This report is concordant with the Consolidated Standards of Reporting Trials (CONSORT) statement (2010).46
Trial design
We undertook a multicentre, parallel-group RCT of HAL compared with conventional RBL in the treatment
of people with symptomatic second- or third-degree (grade II or grade III) haemorrhoids in 17 NHS Trusts in
the UK. Participants were individually randomised to HAL or RBL, in equal proportion at all centres.
Important changes to methods after trial commencement
Recruitment commenced on 12 November 2012, and, following this, in response to early observations,
a number of changes were made to the protocol (see Appendix 1) and trial methods. Between the initial
Research Ethics Committee (REC) approval and study commencement, there were two substantial
amendments clarifying the serious adverse event (SAE) reporting and the expected adverse events.
The protocol was published in BMC Gastroenterology in October 2012.47
In October 2012 (substantial amendment 3; protocol version 4.0), a change was made to the eligibility
criteria to exclude patients with hypercoagulability disorders [in addition to those on warfarin or
clopidogrel bisulfate (clopidogrel)] following a request from one of the Principal Investigators during a site
set-up visit.
In January 2013 (substantial amendment 6; protocol version 5.0), the baseline data collection was changed
to the day of surgery, rather than at randomisation. Sites and treatment arms differed in the time between
randomisation and treatment, and this change was made to standardise the data collection as much as
possible. This also standardised the time between the baseline and the 12-month follow-up, as the follow-up
time point was based on the date of trial treatment.
In March 2013 (substantial amendment 7; protocol version 6.0), we removed one inclusion criterion and
replaced it with three exclusion criteria for clarification. The inclusion criterion ‘Either presenting for the
first time or after failure of one banding’ at sites had caused some confusion at sites and it was also
decided during the review of this criterion that patients with some historical treatments for haemorrhoids
could be included.
The study team, the sponsor and the Trial Steering Committee (TSC) discussed the windows in which
treatment is clinically relevant, and agreed that there should be a difference between surgical and
non-surgical treatment for haemorrhoids (and that dietary advice would not exclude patients). The
amended criteria clarified that all previous surgery for haemorrhoids and more than one injection treatment
or banding in the previous 3 years would lead to exclusion. For non-surgical treatments, > 3 years was
considered a historical event and therefore not relevant to the current research. As one previous banding
was allowed within the protocol, this was also the case for injection treatments, as they were both
non-surgical; one previous course of injection treatment would not mean that patients were excluded.
In April 2013 (substantial amendment 8; protocol version 7.0), we added ‘patients will have at least
24 hours to decide whether to take part’ to the protocol, in order to provide clarification, as it was not
explicitly stated previously. The 24-hour period was an appropriate time frame for the study population
and intervention.
A pre-randomisation questionnaire was introduced in July 2013 (substantial amendment 9; protocol
version 8.0). The Data Monitoring and Ethics Committee (DMEC) suggested that patient-reported
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outcomes can be affected by the knowledge of their allocation. As baseline data collection took place on
the day of surgery (following Substantial Amendment 6), the majority of patients knew their allocation by
this point; the concern was that perceived pain and quality of life (QoL) may differ between the groups
due to expectation bias at this time,48 even though no procedure had yet taken place. The senior trial
statistician reported that the early data did indeed support this hypothesis, in particular with higher
self-reported symptoms in the HAL arm. As a result of this, the protocol was amended to incorporate a
questionnaire to be completed before randomisation.
To improve the questionnaire completion rates at the 12-month follow-up, we introduced a prize draw for
participants who returned the questionnaires in February 2014 (substantial amendment 7; no change to
protocol). We completed three draws of £50 each.
Owing to the long waiting times for the HAL procedure, the dropout rate prior to the procedure was
higher than expected. To account for this attrition, in April 2014 (substantial amendment 12; no change to
protocol) the recruitment target was increased to 370 in order to achieve the sample size of 350 prior
to treatment.
Participants and eligibility criteria
The trial was coordinated from the Clinical Trials Research Unit (CTRU) in the Sheffield School of Health
and Related Research (ScHARR). Delegated study staff located at individual centres identified and
consented potential participants.
The target population was patients referred to collaborating centres for treatment of haemorrhoids.
Potential participants fell into three groups:
1. Patients presenting to the surgical outpatient clinic (SOPC) with symptomatic haemorrhoids that did not
require further tests: this group was identified by the clinical team from the general practitioner (GP) referral
letter and a patient information sheet was sent to them prior to their clinic appointment. If they were willing
to participate then they were consented and randomised when they attended the appointment.
2. Patients presenting to the SOPC with symptomatic haemorrhoids that required further tests to exclude
other diagnoses: this group were identified by the clinician at the clinic appointment and given a
patient information sheet. They underwent the necessary outpatient tests (usually endoscopy) and,
if negative (i.e. the symptoms are due to haemorrhoids), they were contacted by the research nurse
prior to attending their follow-up clinic appointment. They were then randomised and consented when
they reattended the clinic.
3. Patients who returned to SOPC following one unsuccessful RBL: they were identified by the clinician at
their first clinic appointment (when they have RBL) and given a patient information sheet. They were
contacted prior to a follow-up appointment (usually 6 weeks after treatment) by a research nurse.
If they remained symptomatic and were willing to participate, they were consented and randomised
when they reattended.
All potential participants had a minimum of 24 hours in which to decide whether or not they wished to
take part. Patients with investigations excluding pathologies other than haemorrhoids, and all of those
who had undergone RBL, were contacted by the research nurse before the planned follow-up clinic to
ascertain whether or not they met entry criteria and were interested in entering the trial. They would then
be seen by the consultant and research nurse in clinic where recruitment and randomisation took place.
Potential participants were invited to take part in the trial if they were aged ≥ 18 years and had
symptomatic second- or third-degree haemorrhoids.
METHODS
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Patients were excluded if they met any of the following criteria:
l have had previous surgery for haemorrhoids (at any time)
l have had more than one injection treatment for haemorrhoids in the past 3 years
l have had more than one RBL procedure in the past 3 years
l with known perianal sepsis, inflammatory bowel disease, colorectal malignancy, pre-existing sphincter injury
l with an immunodeficiency
l unable to have general or spinal anaesthetic
l currently taking warfarin, clopidogrel or have any other hypercoagulability condition
l pregnant women
l unable to give full informed consent (this may be due to mental capacity or language barriers)
l previously randomised to this trial.
Settings and locations where the data were collected
The CTRU coordinated the follow-up and data collection in collaboration with centres. Participant study
data were collected and recorded on study-specific case report forms (CRFs) by centre research staff, and
then entered on to a remote web-based data capture system at site. To improve the rate of completion,
research nurses could complete the participant questionnaires with the participants at the visit or over the
telephone, or the participants could return the questionnaires by post to the centres at all time points.
Patient questionnaires, at 12 months, could also be completed online and could be returned to the CTRU
by participants for data entry.
Interventions
Participants were randomised to receive either RBL or HAL. Both interventions are established and
well-documented procedures, which are considered standard care by NICE.40,49
Conventional RBL uses a device that allows a rubber band to be applied to each haemorrhoid via a
proctoscope. The device used across sites was a suction device (various manufacturers), but bands can
be applied using a forceps ligator. This rubber band constricts the blood supply causing it to become
ischaemic before being sloughed approximately 1–2 weeks later. The resultant fibrosis reduces any
element of haemorrhoidal prolapse that may have been present. This is a very commonly performed
procedure in all SOPCs; figures from an audit of current practice at Sheffield Teaching Hospitals (STH)
highlighted that prior to the trial over 20 such procedures were carried out every week. The procedure is
a basic surgical skill with which all senior staff are familiar and competent in performing. All surgeons
involved in the study performed this procedure routinely.
Haemorrhoidal artery ligation uses a proctoscope that is modified to incorporate a Doppler transducer.
There are two types of equipment in common use: the HALO (haemorrhoidal artery ligation operation)
device [Agency for Medical Innovations (AMI) HAL Doppler system, CJ Medical, Truro, UK] and the
THD (transanal haemorrhoidal dearterialisation) device (THD Lab, Correggio, Italy). Both devices operate
on the same principle, essentially enabling accurate detection of the haemorrhoidal arteries feeding
the haemorrhoidal cushions. Targeted ligation of the vessels with a suture reduces haemorrhoidal
engorgement. When combined with a ‘pexy’ suture, both bleeding and haemorrhoidal prolapse are
addressed. All of the surgeons participating in the trial ensured that the need for a pexy suture was
routinely assessed and recorded. The procedure is simple, uses existing surgical skills and has a short
learning curve, with the manufacturers recommending at least five mentored cases before independently
practising. All of the surgeons involved in the study had completed this training prior to the start and, in
addition, had carried out more than five procedures prior to delivering the study treatment.
Trial procedures were carried out as soon as possible after randomisation. RBL is a brief procedure, which,
in many cases, can be carried out at the initial clinic visit. By contrast, HAL is an invasive procedure, usually
performed under general anaesthetic, and requires a theatre admission, which may be some considerable
time after assessment. The HubBle trial defined ‘baseline’ as being the date of procedure, and ‘recurrence
at 1 year’ as being from this date onwards.
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Outcomes
Measurement of outcomes
Following consent but prior to randomisation, a participant-completed questionnaire was administered
which included questions relating to pain, symptoms, EQ-5D-5L (European Quality of Life-5 Dimensions,
5-level version), continence and use of pain medications. The research nurse completed a patient assessment
form, which included demographics and details of the haemorrhoids, including previous treatment(s).
The same participant questionnaire was repeated at baseline, defined as the day of the procedure;
in addition, the procedure details CRF was completed by the consultant or the research nurse.
Short-term outcome assessments were completed by participants either via return of a postal questionnaire
or a telephone call with the research nurse at days 1, 7 and 21 post procedure. This covered EQ-5D-5L,
pain and use of pain medication.
Data were collected 6 weeks following the procedure and again at 12 months following the procedure
in order to establish which patients required further treatment for recurrent symptoms or complications.
Participants attended a 6-week clinic visit following the intervention at which they were asked details
regarding GP visits, hospital attendance or further treatment since the procedure; the baseline questionnaire
was also repeated at this time. A clinical assessment was recorded wherein complications, SAEs and further
treatment (planned or completed) were reported; the haemorrhoidal grade was recorded when it was
clinically assessed. The clinician was also asked whether or not, in his/her opinion, the patient’s symptoms
were improved.
Twelve-month data were collected from three sources. Details of further procedures were obtained from
hospitals (by reviewing hospital records and asking the patients’ consultants), by contacting the patients’
GPs and, finally, by questioning the patient via telephone interview or postal questionnaire at 12 months.
Primary outcome measure
The main research question of the study was to ascertain the 1-year incidence of recurrence following HAL
or RBL. The primary outcome was defined as the proportion of patients with recurrent haemorrhoids at
12 months post procedure, as derived from the patient’s self-reported assessment in combination with GP
and hospital records.
The trial was a pragmatic design with a dichotomous outcome. As no validated patient-reported symptom
score exists, we based our definition of recurrence on Shanmugam et al.’s systematic review12 definition:
1. Cured or improved: Symptom free or mild residual symptoms but not requiring further treatment at
the end of study period; or, 2. Unchanged or worse: No symptom improvement and requiring further
intervention or suffered complication or deterioration of symptoms.
This study simplified Shanmugam’s criteria12 into the following question, asked at 12 months by a research
nurse: ‘At the moment, do you feel your symptoms from your haemorrhoids are (1) cured or improved
compared with before starting treatment or (2) unchanged or worse compared with before starting treatment?’
Patients were considered to have recurrent haemorrhoids when any of the following were recorded
(as shown in Figure 1):
i. ‘Unchanged or worse compared with before starting treatment’ at 12 months, as reported by the
patient, or
ii. Any subsequent procedure (RBL, HAL, THD, haemorrhoidectomy, haemorrhoidopexy, haemorrhoidal
injection or other relevant procedure) over the 12 months, or
iii. Presence of any symptoms or events that strongly indicated recurrent haemorrhoids [among patients not
meeting (i) or (ii), as adjudicated by two trial investigators (JT, SB) who were blinded to allocated treatment].
METHODS
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Secondary outcome measures
Secondary end points seek to identify which treatment – HAL or RBL – is the most cost-effective, which
is the least painful procedure with the fewest complications, and which has the greatest effect on the
patient’s QoL. Secondary end points are therefore:
l Persistence of significant symptoms defined analogously to the 12-month outcome.
l Symptom severity score (adapted from Nyström et al.42). This score is the sum of the scores from all
five questions and is therefore a number on a nominal scale in the range of 0 to 15; where an increase
in number is an increase in symptoms.
l HRQoL using the EQ-5D-5L.43 A summary index with a maximum score of 1 can be derived from the
five dimensions by conversion using a table of scores. The maximum score of 1 indicates the best
health state, by contrast with the scores of the individual questions, where higher scores indicate more
severe or frequent problems.
l Continence using the validated Vaizey incontinence score.44 The Vaizey incontinence score is simply the
sum of the scores from all of the seven questions, and is also a number on a nominal scale in the range
of 0–24, for which an increase in number indicates more severe incontinence.
l Pain using a 10-cm VAS, for which ‘0’ is ‘no pain’ and ‘10’ is ‘worst imaginable pain’.
Patient response at 12 months to the primary outcome question:
‘At the moment, do you feel your symptoms from your haemorrhoids are:
1. Cured or improved compared with before starting treatment; or,
2. Unchanged or worse compared with before starting treatment?’
Did the patient have any subsequent
procedure over the 12 months?
Did the patient have any symptoms
or events that strongly indicated
recurrence?
1. Cured or improved
compared with before
starting treatment
No recurrence
Recurrence
No
No
Yes
Yes
2. Unchanged or worse
compared with before
starting treatment
FIGURE 1 Decision tree for recurrence at 1 year.
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l Surgical complications.
l Need for further treatment.
l Clinical appearance of haemorrhoids at proctoscopy following persistent symptoms at 6 weeks.
l Health-care costs/cost-effectiveness/quality-adjusted life-years (QALYs).
The schedule for collecting these end points is shown in Table 1.
Sample size
Assuming that the proportion of patients who experience recurrence following RBL is 30% and following
HAL is 15%, the sample size calculated to detect a difference in recurrence rates with an odds ratio (OR)
of 2 with 80% power and 5% significance was 121 individuals per group. In order to account for any
between-surgeon variation and loss to follow-up, this was increased to 175 per group.
This increase was based on the conservative assumption that there would be 14 surgeons in the trial
(one per centre, although the number of sites was increased) and intraclass correlation (ICC) of 2.5% in
keeping with typical ICCs observed by Ukoumunne et al.50 However, it was considered likely that each
site would have a minimum of two surgeons, in which case the power to detect this difference was
85% (90% power if there was no between-surgeon variation). Because the surgical procedure was well
developed and standardised, ICC was expected to be virtually zero and the proposed sample size was
hoped to have closer to 90% power.
The impact of loss to follow-up was minimal for the primary end point (haemorrhoidal recurrence at
12 months). Patients who did not complete their 12-month follow-up still had their hospital notes reviewed,
and their GP was contacted to ascertain whether or not any complications or operative procedures were
recorded. The only dropout expected was if the patient should die, move out of the area or have no traceable
patient notes; we anticipated this would be less than the 5% that we allowed for in this patient population
(a previous study of RBL that used only clinical follow-up reported a 1-year loss to follow-up of 10%51).
Explanation of any interim analyses and stopping guidelines
No formal interim analyses for efficacy were carried out. However, the safety of the treatments was
assessed by an independent DMEC, the members of which convened annually to review SAEs experienced
by study participants.
TABLE 1 Use of assessment instruments during the trial
Assessment instrument
Time of assessment
Randomisation
Pre-surgery
(baseline) 1 day 7 days 21 days 6 weeks 1 year
EQ-5D–5L ○ ○ ● ● ● ○ ●
Visual analogue pain score ○ ○ ● ● ● ○
Vaizey incontinence score ○ ○ ●
Haemorrhoids symptom score ○ ○ ○ ●
Complications review interview ○ ●a
Health and social care resource-use data ○ ●a
Further treatment questionnaire ○ ●a
Recurrence (primary outcome) ●a
Clinical appearance at proctoscopy
(when applicable)
○
a Supplemented by hospital/GP notes.
○, assessment in clinic; ●, telephone/postal self-report assessment.
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Randomisation and blinding
Randomisation was undertaken using the CTRU’s web-based randomisation system. After consent,
participants were individually randomised, in a 1 : 1 ratio, to either HAL or RBL by a member of the
research team at site. To ensure equal allocation across centres, randomisation was stratified by centre
using permuted blocks of random sizes 2, 4 and 6. Allocation concealment was achieved by ensuring that
the participant identifier was entered, following which the allocation was revealed; no member of the
study team had access to the randomisation schedule during recruitment. The study was open label, with
no blinding of participants, clinicians or research staff attempted.
Statistical methods
Analysis populations
The primary analyses were intention-to-treat (ITT) analyses in which individuals were analysed according
to the treatment to which they were randomised, regardless of whether or not they underwent their
allocated surgery. Secondary analyses were undertaken on a per protocol (PP) basis, which was restricted
to those individuals who complied with the protocol. The categories of non-compliance were eligibility,
missed windows, consent and treatment issues, which included patients who did not receive their
allocated treatment. Safety summaries were reported, based both on randomised and actual treatment
where these differed.
Analysis of 1-year recurrence (primary outcome)
The primary outcome was the recurrence of haemorrhoids at 1 year, as defined above (see Primary
outcome measure). Analyses were undertaken using a random intercept logistic regression model in which
the covariates were treatment allocation, gender, age at surgery and history of previous intervention as
fixed effects; the surgeon was included as a random effect. Further sensitivity analyses assessed whether or
not other baseline characteristics [including symptom score, EQ-5D-5L and body mass index (BMI)] altered
the strength of the treatment effect and/or appeared to modify the treatment effect. ‘Goodness of fit’
of the logistic regression model was assessed using the Hosmer–Lemeshow test.52 ICC coefficients were
calculated to summarise the clustering that may exist around surgeons.
Secondary outcomes
Persistent significant symptoms at 6 weeks
Recurrence at 6 weeks was analysed in the same manner as the primary outcome. Unlike the 12-month
recurrence, no blind review was incorporated, as common symptoms (e.g. severe pain or bleeding) may be
due to the procedure rather than the haemorrhoids.
Haemorrhoid symptom severity score
The severity of haemorrhoidal symptoms was compared using a generalised least squares regression mixed
model using the same covariates as the primary outcome. The prespecified analysis did not include
baseline symptoms as a covariate because of the concerns noted below (see Important Changes to
Methods after Trial Commencement), but sensitivity analyses were also undertaken, which adjusted for
severity at randomisation (when available) and at baseline, and the average of the two. The difference in
symptom severity was compared separately for the 6-week and 12-month time points.
European Quality of Life-5 Dimensions (5-level version) status
Health utility was assessed by the EQ-5D-5L questionnaire using the Value Set for England normative
data.53 EQ-5D-5L was assessed at days 1, 7 and 21. Longitudinal analyses of EQ-5D-5L were conducted as
part of the economic evaluation described below (see Health-economic methods).
Vaizey faecal incontinence score
Incontinence was assessed using the Vaizey inventory and analysed in the same manner as haemorrhoidal
symptoms.
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Pain
Pain was measured using a 10-cm VAS. The VAS scores for HAL and RBL were compared at each time
point using the same methods as the haemorrhoid symptom severity. The VAS was collected at
randomisation, baseline, days 1, 7 and 21, and, finally, at 6 weeks.
Safety outcomes
Complications
The secondary outcome of procedural complications (adverse events such as pain from thromboses,
bleeding requiring consultation, fissuring of the anal canal) elicited during the complications review
interview, or from the patient notes at 6 weeks and 1 year post surgery, was compared between the
two groups at each time point using Poisson regression.
Serious adverse events
An adverse event is recorded as ‘serious’ if it is an untoward occurrence that:
l results in death
l is life-threatening
l requires hospitalisation or prolongation of existing hospitalisation
l results in persistent or significant disability or incapacity
l consists of a congenital anomaly or birth defect, or
l is otherwise considered medically significant by the investigator.
Serious adverse events were reported as the number of events, and the number and percentage of
participants experiencing each event. Each SAE was classified as systemic complication; urinary retention;
pelvic sepsis; or other.
Further treatment
The incidence of the need for further treatment, either surgical or medical, was recorded.
Clinical appearance at proctoscopy (if persistent significant symptoms)
Data were recorded for patients who underwent examination at 6 weeks. This included the clinical
assessment of grade and the change from baseline.
Additional/post hoc analyses
Additional, unplanned analyses were undertaken to address questions that arose during the trial
progression. These were undertaken in a similar manner to the analyses described above, with adjusted
analyses using the same covariates unless otherwise stated.
General considerations
All analyses were undertaken on an ITT basis unless otherwise stated. All confidence intervals (CIs) were
two-sided 95% intervals, and all statistical hypotheses were two-sided tests. Continuous measures
were summarised as mean (standard deviation, SD) or median (interquartile range, IQR) as appropriate to
the distribution of the data. Categorical data were summarised as numbers and percentages.
Health-economic methods
Background
We collected data as part of the trial that allowed us to conduct a full economic evaluation. The main
economic analysis focused on estimating the incremental cost per QALY of HAL compared with RBL over
the 12-month follow-up period of the trial. We have also presented results in terms of the incremental cost
per recurrence avoided.
METHODS
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Patients were asked to complete the EQ-5D-5L instrument at pre-randomisation, pre-surgery (baseline) and
subsequent time points following the treatment. The UK population tariffs were then used to calculate
QALYs for each patient.54 EQ-5D has been applied in previous studies in this area55 and appears to be
sensitive to changes in patient outcomes. Pain was likely to be one of the main symptoms in which we
might expect the treatments to differ and this is well reflected in the EQ-5D-5L instrument.
Overview
Aim
The aim of the economic evaluation was to assess the cost-effectiveness of HAL compared with RBL in
terms of incremental cost per QALYs over 12 months’ follow-up.
Methods
Perspective
The economic evaluation took a NHS and Personal Social Services perspective as per NICE recommendations.49
The estimated resource use covers the period in which a patient is in hospital, post discharge and primary care
services, including costs related to recurrence of haemorrhoids.
Method of economic evaluation
We conducted a cost–utility analysis (CUA) as the main method of economic evaluation, for which the
outcome was expressed in QALYs. We then carried out a cost-effectiveness analysis (CEA) for which
the outcome was expressed in terms of incremental cost per recurrence avoided with HAL compared with
RBL. All health-economic analyses were conducted on an ITT basis, including all of the patients randomised
to each group. All analyses were conducted using Stata version 13 (StataCorp LP, College Station, TX, USA).
Outcomes
The EQ-5D-5L was used for collecting QoL data at seven time points: pre-randomisation, baseline, 1 day,
7 days, 21 days, 6 weeks and 12 months. The EQ-5D is a generic standardised instrument for measuring
HRQoL. The EQ-5D-5L is a five-level version of the EQ-5D, which was recently launched to improve
sensitivity of the descriptive system while keeping the same structure of the original instrument [European
Quality of Life-5 Dimensions, 3-level version (EQ-5D-3L)].53 The EQ-5D-5L utility scores we applied were
obtained using recently published tariffs based on the UK general public.54 The individual patient-level
QALYs were calculated from EQ-5D-5L scores at baseline and subsequent follow-up time points for 1 year
using the area under the curve method. Discounting was not used for the calculated QALYs in the main
analyses, as it was carried out for a 1-year time horizon. We examined the relationship between EQ-5D-5L
and symptom scores to check the appropriateness of using this instrument in this setting.
Costs
The costing approach followed the standard stages used in economic evaluation and involves identification
of resource use, measurement and valuation.56
Resource use
Identification of resource use
We identified a range of resource use based on different CRFs and questionnaires used for collecting
relevant data at different time points of the trial follow-up. These include the procedure details,
clinical assessment at 6 weeks, consultant questionnaire at year, GP questionnaire at 1 year, and
participant questionnaire at 1-year time points. The resource use identified is categorised in the following
three domains:
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Resource use during rubber band ligation procedure
l Procedure event.
l Procedural complications.
l Postprocedural complications.
l Hospital admissions.
l Medication on discharge.
Resource use during haemorrhoidal artery ligation procedure
l Anaesthetic.
l Procedure event.
l Intraoperative complications.
l Hospital admissions.
l Postoperative complications.
l Medication on discharge.
Post discharge
l Outpatient treatments.
l Surgical treatments.
l Emergency admissions.
l Contact with health professionals.
l Further treatments and medications.
l Recurrence treatments.
Measurement of resources
All events relating to resource use identified were recorded throughout the trial using different data
collection forms at different time points. These were the procedure details form at day 0, clinical assessment
form at 6 weeks, consultant questionnaire at 1 year, and GP questionnaire at 1 year. The instruments used
for measuring resource use within the trial are provided in Appendix 2. For the HAL procedure event,
resource use included the type of anaesthetic used, grade of operating surgeon, whether or not the
procedure was supervised by a consultant, timing for surgery, and overall time spent in the operating
theatre. Detailed medications prescribed on discharge or as further treatment were also recorded.
Data on hospital admissions and type of admissions were recorded, and data on the durations of
admissions were measured based on the NHS average estimates for some events, such as non-elective
emergency admissions. Visits for health-care professionals including consultants, GPs and general practice
nurses were recorded. However, the duration of each visit was not recorded and therefore average
estimates were used based on the NHS or the Personal Social Services Research Unit (PSSRU), University of
Kent approaches, where relevant.57
Valuation of resources
Costs were estimated in UK pound sterling based on the financial year 2014–15. Unit costs were applied
for each resource-use event at the individual patient level to calculate the total cost of resource use over a
12 months’ time horizon.
Unit costs
Procedure event unit cost
The unit cost for a RBL procedure event was estimated as an outpatient procedure, and was obtained from
the National schedule of NHS reference costs for 2014–15.58 Admissions unit costs were also obtained
from the NHS reference costs.58 For a HAL procedure, a microcosting approach was applied, based on cost
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per minute in procedure, recovery time and theatre overhead per minute. The cost per minute in
procedure was based on the actual time spent by clinical staff operating and supervising the procedure
and the PSSRU staff unit cost. The unit costs for the surgical kits used in the HAL procedure were obtained
from the NHS supply system. Blood transfusion unit cost was obtained from the blood transfusion costing
statement issued by NICE.59 Unit costs for medications prescribed on discharge were calculated using the
cost of generic drugs from the British National Formulary (BNF) 2015.60
Post discharge unit cost
The unit costs for surgical treatments following recurrence of haemorrhoids were obtained from different
sources. The cost for SH procedure was taken from McKenzie et al.55 and adjusted for inflation. Unit costs
for excisional haemorrhoidectomy (EH) and RBL in the theatre procedures were estimated using the NHS
reference costs 2014–15.58 The unit costs for repeated RBL and HAL procedures were calculated using the
average cost for participants within the HubBLe trial. For contacts with health-care professionals, the
PSSRU unit costs were applied.
All unit costs used in the economic analyses are summarised in Tables 2–4.
Outcomes
Recurrence is the primary outcome for this study (please refer to Primary Outcome Measure, above, for
details). For the economic evaluation, the difference in the number of recurrence between the intervention
group (HAL) and the control group (RBL) was used as an outcome for assessing the cost-effectiveness in
terms of cost per recurrence avoided.
Analysis
The base-case analysis was based on imputed data, whereas complete-case analysis was conducted as a
sensitivity analysis. The economic analysis involves CUA as a primary analysis, and a CEA was performed as
a secondary analysis. Both analyses involve the estimation of differential costs and differential outcomes.
A subgroup analysis was performed for patients with new haemorrhoids and patients with recurrence
following RBL before randomisation. Different sensitivity analyses were performed to address uncertainty
associated with the estimates from our base-case analysis.
TABLE 2 Unit cost applied for valuation of resource use: RBL procedure
Event Description Unit cost (£) Source Note
Procedure cost RBL procedure 109.00 UK NHS reference
costs 2014–1558
Outpatient procedure
Blood transfusion 170.14 NICE 201559 Blood transfusion costing statement
Hospital admission Inpatient bed-day 303.00 UK NHS reference
costs 2014–1558
–
Medication prescribed
post procedure
Paracetamol 1.27 BNF 201560 500 mg, 32-tablet pack
Co-codamol 6.73 BNF 201560 30/500 mg, 100-tablet pack
Codeine 1.23 BNF 201560 15 mg, 28-tablet pack
NSAID 3.50 BNF 201560 Ibuprofen 200mg, 84-tablet pack
Tramadol 14.10 BNF 201560 100 mg, 30-tablet pack
Laxative 3.82 BNF 201560 Bisacodyl 5 mg, 100-tablet pack
Antibiotic 5.03 BNF 201560 Augmentina 375mg, 21-tablet pack
NSAID, non-steroidal anti-inflammatory drug.
a Augmentin = amoxicillin and clavulanate potassium.
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TABLE 3 Unit cost applied for valuation of resource use: HAL procedure
Event Description Unit cost (£) Source Note
Anaesthetic General and local
anaesthetic
100.08 UK NHS reference
costs 2014–1558
Spinal anaesthetic 200.00
HAL procedure Consultant cost per minute 2.30 PSSRU 201557 Includes costs of qualifications
Associate specialist cost
per minute
2.13 PSSRU 201557 Includes costs of qualifications
Surgical trainee cost
per minute
2.13 PSSRU 201557 Includes costs of qualifications
Fellow cost per minute 2.13 PSSRU 201557 Includes costs of qualifications
Specialist nurse cost
per minute
1.52 PSSRU 201557 Includes costs of qualifications
Research nurse cost
per minute
1.52 PSSRU 201557 Includes costs of qualifications
Registrar cost per minute 1.20 PSSRU 201557 Includes costs of qualifications
Scrub nurse cost
per minute
1.52 PSSRU 201557 Includes costs of qualifications
Cost per minute
in recovery
0.41 McKenzie 200955 Adjusted for inflation
Cost per minute for
theatre overheads
13.74 McKenzie 200955 Adjusted for inflation
Operating event Outpatient procedure 109.00 PSSRU 201557
Surgical kit for HAL
procedure
432.00 NHS Supply
system
Excision of skin tags 109.00 UK NHS reference
costs 2014–1558
Outpatient procedure
Procedure cost Cost of HAL surgery
(used in sensitivity analysis)
1128.00 UK NHS reference
costs 2014–1558
Intermediate anal procedure
(FZ22B-E)
Hospital admission Inpatient bed-day 303.00 UK NHS reference
costs 2014–1558
Need for blood transfusion 170.14 NICE 201559 Blood transfusion costing
statement
Medication on
discharge
Paracetamol 1.27 BNF 201560 500 mg, 32-tablet pack
Co-codamol 6.73 BNF 201560 30/500 mg, 100-tablet pack
Codeine 1.23 BNF 201560 15 mg, 28-tablet pack
NSAID 3.50 BNF 201560 Ibuprofen 200mg, 84-tablet pack
Tramadol 14.10 BNF 201560 100 mg, 30-tablet pack
Laxative 3.82 BNF 201560 Bisacodyl 5 mg, 100-tablet pack
Antibiotic 5.03 BNF 201560 Augmentin 375mg, 21-tablet pack
GTN paste 39.30 BNF 201560 GTN ointment 0.4%, 30 g
Diltiazem paste 73.83 BNF 201560 2% diltiazem cream
GTN, glyceryl trinitrate; NSAID, non-steroidal anti-inflammatory drug.
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Resource use
Resource-use data were used for costing the different clinical events and service use at individual patient
level. Where RBL or HAL procedures are repeated following recurrence after the initial procedure within
this trial, the mean level of resource use within the HubBLe trial was applied.
Difference in costs
The mean total costs and the differences in mean total costs between HAL and RBL groups were analysed
using complete-case analysis and descriptively reported alongside the numbers of complete cases,
their percentage from the total participants per group, SDs and CIs. The mean costs for each group of
resource-use items were similarly reported in tabular format.
TABLE 4 Unit cost applied for valuation of resource use: post discharge (RBL or HAL)
Event Description Unit cost (£) Source Note
Outpatient treatment Outpatient visit 114.00 UK NHS reference
costs 2014–1558
Injection sclerotherapy 4.79 BNF 201560 Phenol 5% injection,
5-ml ampoule
EH 1508.72 UK NHS reference
costs 2014–1558
FZ22E (elective)
SH 2478.42 McKenzie 200955 Adjusted for inflation
RBL (in theatre) 1338.45 UK NHS reference
costs 2014–1558
FZ22E (elective)
Other elective
procedure
1338.45 UK NHS reference
costs 2014–1558
FZ23A
Emergency admissions Emergency admission
for symptoms related to
RBL/HAL
1565.00 UK NHS reference
costs 2014–1558
Non-elective
Blood transfusion 170.14 NICE 201559 Blood transfusion costing
statement
Emergency operation 2761.00 UK NHS reference
costs 2014–1558
FZ23A
Contact with health
professionals
GP visit 46.00 PSSRU 201557
Nurse visit (GP practice) 13.70 PSSRU 201557 Based on 15.5 minutes
per visit
Consultant visit 114.00 UK NHS reference
costs 2014–1558
Further treatments GTN paste 39.30 BNF 201560 GTN ointment 0.4%, 30 g
Diltiazem paste 73.83 BNF 201560 2% Diltiazem cream
Recurrence treatment costs Proctoscopy at 6 weeks’
assessments
10.99
RBL after recurrence 523.16 Mean RBL cost
within HubBLe
trial
Admissions with
complications
1565.00 UK NHS reference
costs 2014–1558
Non-elective
GTN, glyceryl trinitrate.
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Missing data
Missing data may lead to misleading estimates of within-trial CEA, and in this context complete-case
analysis is undesirable, as it would reduce the sample size and may affect the power of the study.61
To check the patterns of missing data, we performed two types of descriptive analyses of missing data:
(1) number of missing data by treatment group to assess whether or not missing data differ by group; and
(2) missing data patterns to determine whether or not data are missing for all items or individual items of
utility scores and resource-use items over the trial follow-up.61 The multiple imputation chained equation
(MICE) method with predictive mean matching was utilised for imputing missing values of costs, QALYs
and baseline utility.61 Age, gender, grade of haemorrhoids, site code and randomisation group were used
as imputation variables in this model. The number of imputations specified in this model was 53, based on
the highest percentage of missing data for the variables of interest (baseline utility, QALYs and total cost).61
The imputation was performed per randomisation arm, for all imputed variables, except baseline utility, for
which imputation was performed across all observations. This model allowed the prediction of missing
values from the posterior distribution of missing observations, given the values of observed data from the
imputation variables.
Cost–utility analysis
Cost–utility analysis was performed as the primary economic analysis for estimating the cost-effectiveness
of HAL compared with RBL. A seemingly unrelated regression (SUR) model was fitted for estimating
differential costs and differential QALYs, while controlling for imbalance in baseline utility and taking
into account the correlation between cost and QALYs. Controlling for imbalance in baseline utility is
recommended as good practice for within-trial CEA.62 The fitted SUR model also provided the estimation
of full variance–covariance matrix which was further used for addressing uncertainty using the parametric
method.63 In addition to the advantage of controlling for heterogeneity between patients (such as an
imbalance in baseline utility) offered by traditional ordinary least squares (OLS) regression, SUR offers two
additional advantages: it allows (1) the use of different sets of covariates for cost and effectiveness (QALYs)
to assess their joint impact on cost-effectiveness simultaneously; and (2) the testing of joint hypothesis
regarding the important coefficients (difference in costs and QALYs) across the two regression equations.63
The incremental cost-effectiveness ratio (ICER) was estimated from the SUR regression output, based on
analysis of imputed data for the base case. The ICER is then compared with NICE cost-effectiveness
threshold range of £20,000–30,000 per QALY gained.
To address uncertainty around our CUA estimates, a number of approaches were used based on the
parametric method. We used five key parameters from the SUR regression output and conducted a fully
parametric CUA. These parameters were difference in mean QALYs, standard error (SE) of the mean
differential QALYs, difference in mean costs, SE of mean differential costs, and covariance between costs
and QALYs. From these parameters, we produced three different graphs: the cost-effectiveness acceptability
curve (CEAC), the cost-effectiveness confidence ellipses and the net benefit line with CIs. The higher bound
of NICE cost-effectiveness threshold of £30,000 per QALY was used as a standard decision rule in this
analysis for illustrative purposes. The cost-effectiveness threshold was varied from £0 to £140,000 for
addressing uncertainty associated with the cost–utility estimates across different levels of willingness to pay.
Combined CEAC curves were generated from the subgroup analysis for patients with new haemorrhoids
and patients with recurrence following RBL to allow for easy comparisons. We also conducted an
additional analysis by controlling for the grade of haemorrhoids in addition to baseline utility within the
SUR model. This allowed us to assess the effect of the grade of haemorrhoids on our CUA in terms of
differential cost, differential QALYs and the ICER.
Cost-effectiveness analysis
The CEA followed the standard approach for which the total difference in costs was divided by the
difference in recurrence to generate the incremental cost per recurrence avoided. However, it should be
noted that treatments differed following recurrence, and these were also captured by our costing approach
and constitute a key part within the primary CUA.
METHODS
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Sensitivity analyses
We performed a number of sensitivity analyses to assess the robustness of our estimates and address some
issues, which might be associated with our costing approach and unit costs applied in the base-case
analysis. The main sensitivity analysis was based on using the NHS reference costs for HAL procedure rather
than the microcosting approach. In this scenario, HAL was considered as a day case intermediate anal
procedure and the cost associated with this Healthcare Resource Group (HRG) was applied. This was
assumed to include all of the other procedure-related costs, including the anaesthetic cost, the surgical kits,
staff time and theatre overhead cost as per the HRG costing approach. A similar imputation model and SUR
were used for estimating differential cost, differential QALYs and the ICER for this scenario of sensitivity
analysis. We also produced a CEAC curve using the same methods applied in our base-case analysis.
An additional sensitivity analysis was undertaken by controlling for the grade of haemorrhoids, in addition
to baseline utility, using the same regression model. This was carried out to assess the interaction effect of
the grade of haemorrhoids on our CUA. The results from this form of sensitivity analysis are presented in
terms of ICER.
We also carried out a sensitivity analysis by conducting another scenario of CUA using complete cases.
A similar SUR model was run for estimating differential costs, differential QALYs and the ICER based on
complete cases only. The results of this analysis were reported in a tabular format.
Another sensitivity analysis was conducted by estimating a utility decrement for each subsequent procedure
performed during the trial follow-up. As the EQ-5D-5L questionnaire was completed at particular follow-up
time points that did not coincide with any follow-up procedures, estimated QALY decrements were applied.
The QALY decrements following subsequent HAL or RBL procedures were estimated using mean utility
scores from the trial at baseline, day 1 and day 7. For SH and EH utility decrements were taken from a
published UK study.2 Utility scores during the recovery period of 0.756 for EH and 0.767 for SH were used
for estimating QALY decrements.2 QALY decrements were applied at the individual patient-level data and a
regression analysis was run using the same model specification in our base-case analysis.
Long-term cost-effectiveness
A long-term extrapolation analysis was undertaken to assess the cost-effectiveness of HAL compared with
RBL beyond the trial time horizon. The cost and utility data reported at 1-year follow-up within the trial were
used in combination with external data to estimate longer-term costs and QALYs. A time horizon of 3 years
beyond the trial was chosen for this analysis. This choice of time horizon was driven by data from external
studies for which recurrence data were available over this follow-up time. We constructed a three-health
states Markov model for extrapolating within-trial cost–utility analyses to long-term cost-effectiveness.
To maintain consistency with the trial analyses, health states were chosen based on the primary outcome
of the trial – recurrence. Heath states included were new haemorrhoids, recurrence and no recurrence.
The extrapolation model structure is shown in Figure 2.
New
haemorrhoids
Recurrence
No recurrence
FIGURE 2 Extrapolation model structure.
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Regression analysis was used to estimate costs and utilities from the trial data using a similar SUR model
described earlier, with recurrence at baseline added as a covariate. This allowed us to estimate costs and
utilities by health state. We assumed that costs and outcomes follow the same pattern observed within the
trial for the purpose of these extrapolation analyses. For instance, the mean costs and QALYs for patients
with recurrence following RBL after 1 year and treated with further procedures were assumed to be same.
Costs and health benefits (utilities) occur at different time points within the long-term time horizon of this
analysis. We used the UK Treasury discount rate of 3.5% per year for discounting all future costs and
QALYs as recommended by NICE.49
The annual probability of recurrence for years 1–3 beyond the trial were estimated from two studies3,37
that have reported long-term recurrence estimates. For RBL, the annual probability of recurrence was
calculated from a retrospective study3 that reported 4 years’ follow-up (n = 805). For HAL, the probability
of recurrence was calculated at 5-year follow-up in a study37 that assessed the long-term success rates for
treating patients with grade II and III haemorrhoids following Doppler-guided HAL (n = 100).37 The mean
total costs over four years, per patient, within each group (HAL and RBL) were calculated based on the
annual probabilities of transition between health states. The mean total QALYs over the same period were
similarly estimated and adjusted for recurrence. The long-term ICER was then estimated from the model
and is reported below (see Long-term cost-effectiveness).
A probabilistic sensitivity analysis (PSA) was performed to address the uncertainty around parameter
estimates from external sources (i.e. long-term recurrence rates). The PSA was run on 1000 Monte Carlo
simulations. The distribution of costs and QALYs used in the PSA simulations were estimated from the
regression analysis on the trial data.
Patient and public involvement
We were committed to involving service users at each stage of our research, from design to dissemination.
From our patient and public consultation event, we identified an individual who was willing to join the
grant application team. This person attended the TSC meetings in order to provide input into study
oversight and have commented on the report, particularly the plain language summary, and the patient
view regarding the choice of treatment. We also had input from service users with regards to the study
design, including some of the patient questionnaires and the length of follow-up involved, and sought
the TSC member’s opinion on study documents submitted to the REC, both initially and relating to
protocol amendments.
METHODS
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Chapter 3 Results
Recruitment and participant flow
Participants who were randomly assigned, received intended treatment and
were analysed for the primary outcome
Recruitment to the trial is represented in Figure 3. A total of 372 participants were randomly assigned to
receive RBL or HAL; 187 patients were allocated to receive RBL, and 185 were allocated to receive HAL.
Two of these participants (both randomised to RBL) were removed from the trial completely, as they were
ineligible at the time of consent; therefore, a total of 370 participants were entered into the trial. In total,
969 patients were screened for entry into the trial and the reasons for non-recruitment are shown in Table 5.
Patient preference was the main reason for non-consent by patients, with 128 patients opting for RBL and
70 patients opting for HAL.
Losses and exclusions after randomisation
A total of 340 participants received treatment as part of the trial and the participant flow is shown in
Figure 4; reasons for withdrawal during the trial are provided in Table 6. Primary outcome data were
collected for 337 participants (161 HAL and 176 RBL): 256 patient questionnaires were returned
at 12 months; 236 GP forms were returned at 12 months, and 337 consultant forms were completed at
12 months. There were 183 participants where all 3 of the 12 months forms were completed/returned.
Dates defining the periods of recruitment and follow-up
The first site to open to recruitment was STH NHS Foundation Trust on 9 September 2012, and
recruitment finished at all sites on 6 May 2014. Follow-up was due to end 1 year after the end of
recruitment but to allow for the delay in receiving the trial treatment we extended this period and the
follow-up was completed at sites on 28 August 2015.
Table 7 shows the duration between randomisation and treatment (waiting time) by treatment group for
the trial. These data do not include individuals who withdrew prior to treatment; 24 participants withdrew
prior to the procedure in the HAL group, compared with six (eligible) participants in the RBL group. In the
RBL group, 114 of 179 (63.4%) participants received treatment on the same day as they were randomised
(0 days), whereas none of the HAL group participants was treated on the same day. Although the maximum
waiting time is greater for RBL, the mean and median shows that waiting times are higher for HAL.
Baseline data
The characteristics of the participants included in the final analysis is shown in Table 8. The groups appear
balanced at baseline in regards to gender, age, BMI, the grade of haemorrhoids and previous treatment
for haemorrhoids.
The majority of the procedures were conducted by consultant or equivalent (clinician accredited for
independent practice, including a clinical nurse specialist), or supervised by a consultant (87% for RBL and
96% for HAL). There were a few cases that were carried out by a trainee doctor. However, these trainees
met our pre-existing competencies.
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Patients screened
(n = 969)
Eligible patients
(n = 773)
Did not meet 
eligibility criteria
(n = 196)
Did not consent
(n = 401)
Patients randomised
(n = 372)
Withdrawn as
not eligible
(n = 2)
Withdrawal
prior to
procedure
(n = 6)
Withdrawal
after procedure
(n = 3)
Patient data 
not obtained
(n = 46)
Randomised to RBL
(n = 187)
Received RBL
(n = 175)
Switched to HAL
(n = 4)
Baseline
• Pre-randomisation questionnaire, n = 86
• Baseline clinical assessment, n = 182
• Baseline questionnaire, n = 149
Short-term outcome assessments
• Day 1 questionnaire, n = 162
• Day 7 questionnaire, n = 157
• Day 21 questionnaire, n = 151
Outcome assessments at routine 
clinical follow-up
• 6-week clinical assessment, n = 150
• 6-week questionnaire, n = 144
• 12-month consultant questionnaire, 
   n = 176
• 12-month participant questionnaire, 
   n = 131
• 12-month GP questionnaire, n = 122
Included in primary analysis
(n = 176)
Primary outcome assessment
Withdrawal
prior to
procedure
(n = 24)
Patient data 
not obtained
(n = 36)
Randomised to HAL
(n = 185)
Received HAL
(n = 158)
Switched to RBL
(n = 3)
Baseline
• Pre-randomisation questionnaire, n = 89
• Baseline clinical assessment, n = 166
• Baseline questionnaire, n = 152
Short-term outcome assessments
• Day 1 questionnaire, n = 141
• Day 7 questionnaire, n = 133
• Day 21 questionnaire, n = 129
Outcome assessments at routine 
clinical follow-up
• 6-week clinical assessment, n = 143
• 6-week questionnaire, n = 137
• 12-month consultant questionnaire, 
   n = 161
• 12-month participant questionnaire, 
   n = 125
• 12-month GP questionnaire, n = 114
Included in primary analysis
(n = 161)
Primary outcome assessments
FIGURE 4 Flow chart summarising the numbers of each type of questionnaire completed throughout the trial.
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TABLE 6 Reasons for participant withdrawal during the trial
Reason for withdrawal
Treatment group
HAL (n= 24) RBL (n= 11)
Prior to procedure
Found to be ineligible during baseline assessments 0 2
Participant withdrew consent 15 3
Lost to follow-up prior to procedure 6 2
Symptoms resolved 2 1
Ineligible at time of procedure 1 0
After procedure
Participant withdrew consent 0 3
TABLE 5 Reasons for non-recruitment to the trial for eligible patients
Reason Frequency
Patient preference 251
Patient preference for RBL 128
Patient preference for HAL 70
Patient preference for other surgery 5
Patient preference for immediate treatment 3
Patient preference related to general anaesthetic 6
Patient did not want any intervention or treatment 39
Clinical decision 41
Patient did not attend appointment/uncontactable 26
Patient unsure or declined (no further reason given) 29
Other reason 12
Unknown 42
Total 401
TABLE 7 Duration between randomisation and treatment in the trial (waiting time)
Treatment group
Waiting time (days)
Minimum Maximum Mean Median
HAL 2 276 75.9 62
RBL 0 413 20.3 0
RESULTS
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Numbers analysed
The ITT population, in which patients were analysed by their original assigned groups, included all
161 participants in the HAL arm and 176 in the RBL arm for whom recurrence data were available from
either the patient, clinician or GP. Of these, the patient-completed questionnaire was returned for 125 and
131 participants in the HAL and RBL groups, respectively. The number of participants included in each
analysis is provided for each measure in this section.
Outcomes and estimation
Recurrence (primary outcome)
The overall proportion of participants with a recurrence at 12 months was 49% in the RBL arm compared
with 30% in the HAL arm (absolute difference 19.6%; adjusted OR 2.23, 95% CI 1.42 to 3.51;
p = 0.0005). The breakdown of recurrences, overall and by criterion, is presented in Table 9. Self-reported
recurrence rates were almost identical, with 29% of respondents in both arms stating that they
believed that their haemorrhoids had either improved or been cured (adjusted OR for self-reported
recurrence = 1.06, 95% CI 0.60 to 1.85; p = 0.85). The increased recurrence associated with RBL is mainly
attributable to the high rate of additional procedures undertaken following the initial procedure [33%,
compared with 14% in the HAL group (adjusted OR for further procedure = 2.86, 95% CI 1.65 to 4.93;
p < 0.001)]. A further three (2%) participants in the RBL arm were considered to have symptoms that were
consistent with recurrent haemorrhoids following blind review. In two cases the participants were recorded
as possibly requiring further treatment at their 6-week visit but were subsequently lost to follow-up; a third
patient had been hospitalised twice for excessive bleeding, but had not undergone treatment.
TABLE 8 Baseline demographical data by randomised group
Demographic Value
Treatment group
RBL (n= 176) HAL (n= 161)
Gender Male (%) 99 (56) 85 (53)
Female (%) 77 (44) 76 (47)
Age Mean (SD) 49.0 (12.9) 48.5 (13.5)
Median (IQR) 50.5 (38.5–58.0) 49.0 (38.0–60.0)
Range 21.9–79.3 20.2–74.6
BMI Mean (SD) 28.0 (5.5) 28.2 (7.1)
Median (IQR) 27.0 (24.4–31.7) 26.8 (24.1–30.0)
Range 17.4–44.9 18.8–67.4
Grade II (%) 115 (65) 92 (57)
III (%) 60 (34) 68 (42)
Not recorded (%) 1 (0.6) 1 (0.6)
Previous treatment No (%) 124 (70) 124 (77)
Yes (%) 52 (30) 36 (22)
Not recorded 0 1 (0.6)
Grade of surgeon undertaking
procedure
Consultant or equivalent (%) 148 (84) 121 (75)
Junior trainee, supervised by consultant (%) 6 (3) 34 (21)
Junior trainee, not supervised by consultant (%) 22 (13) 6 (4)
DOI: 10.3310/hta20880 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 88
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
Sensitivity analyses were undertaken in which alternative covariates (EQ-5D-5L at randomisation or
preoperative, BMI at randomisation, and grade of haemorrhoids at randomisation) were adjusted for;
doing so yielded reasonable consistency in the ORs (range 2.05–2.81), all of which remained statistically
significant. The PP analysis again provided a similar OR (2.21, 95% CI 1.38 to 3.54; p = 0.001).
Of the baseline covariates assessed, none had a statistically significant association with recurrence.
Recurrences were more common, however, among participants who were male, had grade III haemorrhoids,
had undergone previous treatment and had higher symptom scores.
Among the 80 participants who required a further intervention, the majority of participants underwent a
single procedure. In most cases this was RBL, as described in Table 9, although some variation was noted
across centres as described in Table 10: as the primary interest is to document second-line treatment, the
treatment groups here refer to treatment, as received, as opposed to ‘as randomised’, which was reported
previously. As RBL is a brief procedure with (relatively) minimal inconvenience to the patient, it could be
argued that a second-line RBL is not itself indicative of a recurrence because the initial haemorrhoids
remain incompletely treated. Consequently, an additional (and unplanned) analysis investigated the extent
to which recurrence differed if follow-up RBL were not considered a recurrence. In total, 45 participants
(31 in the RBL arm, 11 in HAL) underwent RBL as follow-up procedure. Of the 31 patients who underwent
TABLE 9 Recurrence at 1 year
Recurrence
Treatment group
RBL (n= 176) HAL (n= 161)
Overall recurrence (%) 87 (49) 48 (30)
Criteria for recurrencea (%)
Self-reported recurrence (%) 37 (29b) 34 (29b)
Subsequent procedure for haemorrhoids (%) 57 (33) 23 (14)
RBL 31 (18) 14 (9)
HAL 23 (13) 7 (4)
EH 4 (2) 7 (4)
SH 2 (1) 1 (1)
From blinded review (%) 3 (2) 0
a More than one may apply.
b Denominator is patients returning questionnaire.
TABLE 10 Type of second procedure by treating centre
Site
Treatment group
RBL (N= 175) HAL (N= 162)
n RBL HAL Haemorrhoidectomy n RBL HAL Haemorrhoidectomy
Sheffield 39 8 12 0 34 3 0 0
Birmingham 34 8 0 2 31 5 2 2
Oxford 28 4 2 1 29 2 4 3
Liverpool 21 3 2 0 23 2 2 0
North Tees 13 2 0 1 10 1 0 0
Other centres 40 6 6 2 35 1 0 3
Centres included have at least 10 participants per arm; the remainder are classified as ‘other’.
RESULTS
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repeat RBL, six considered their haemorrhoids to be unchanged or worse at 1 year; three underwent
further procedures; and one was considered a recurrence based on blind review. In the HAL arm, 8 of the
11 participants who were undergoing subsequent RBL considered their haemorrhoids to be unchanged or
worse at 1 year and two participants underwent further procedures. Thus, if subsequent RBL were not
considered a recurrence, the number with recurrent haemorrhoids is 66 (37.5%) in the RBL arm and
44 (27.3%) in the HAL arm (adjusted OR 1.53, 95% CI 0.96 to 2.44; p = 0.071). If a single HAL is
compared with multiple RBLs the number with recurrent haemorrhoids is 66 (37.5%) in the RBL arm and
48 (30%) in the HAL arm (adjusted OR 1.35, 95% CI 0.85–2.15; p = 0.20).
Persistent significant symptoms at 6 weeks
At 6 weeks, data were available for 150 participants in the RBL arm and 143 in the HAL arm: 43 (24%)
participants in the RBL arm reported their haemorrhoids as being unchanged or worse compared with
12 (7%) in the HAL arm; additionally, one participant in each arm had subsequently undergone RBL,
thus resulting in the overall number of patients with persistent symptoms being 44 (29%) compared with
13 (9%) (adjusted OR 4.35, 95% CI 2.19 to 8.65; p < 0.001).
Haemorrhoid symptom severity score
The haemorrhoid symptom severity scores are summarised in Table 11 and displayed graphically in Figure 5:
higher scores indicate more severe symptoms. At 6 weeks, haemorrhoids symptom severity scores were
higher in the RBL group, indicating that short-term symptoms were less pronounced following HAL. The
mean (SD) scores were 4.0 (3.5) in the RBL group and 3.0 (3.1) in the HAL group, with an adjusted mean
difference of 1.0 (95% CI 0.3 to 1.8; p = 0.010). No difference was apparent at 1 year, with the mean (SD)
being 3.6 (3.2) for RBL and 3.6 (3.3) for HAL (adjusted difference = 0.0, 95% CI –0.8 to 0.8; p = 0.98).
A further (post hoc) analysis looked at the proportion of participants whose symptom score was either ‘0’
or ‘1’, as this corresponds to the definition used by Nyström et al.42 These numbers are shown in Table 12.
The proportions are consistent with the previous analysis, with a greater proportion of participants in the
HAL arm reporting either a score of 0 or 1 at 6 weeks.
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FIGURE 5 Haemorrhoid symptom severity scores. Note that the area of data points is proportional to the number
of participants with that value. Vertical lines represent median and IQR.
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European Quality of Life-5 Dimensions (5-level version)
The EQ-5D-5L health tariff is summarised in Table 13 and Figure 6: higher figures indicate a better health
state. Prior to procedure, the mean health utility was around 0.9 in both groups but declined at days 1 and
7 in the HAL group. For RBL the mean (SD) at 1 day was 0.84 (0.19) and at 7 days 0.92 (0.15); in other
words, health state was reduced for the first day but had reverted back at 1 week. By contrast, the mean
health state for HAL had not returned to baseline values by 7 days, with the mean (SD) being 0.76 (0.22)
and 0.83 (0.18) at 1 and 7 days, respectively. The adjusted mean differences were 0.08 (95% CI 0.04 to
0.13; p < 0.001) at 1 day and 0.08 (95% CI 0.05 to 0.12; p < 0.001) at 7 days. The two arms were nearly
similar with no statistical differences (and above baseline values) at all time points from day 21 onwards.
The EQ-5D-5L inventory was also used to derive the health state used in QALYs that are reported within
the health-economic analysis in the following section.
TABLE 11 Participants with haemorrhoid symptom severity scores
Time point
Treatment group
Difference (95% CI); p-valueRBL HAL
Randomisation
n 83 80
Mean (SD) 6.5 (3.2) 6.4 (3.4)
Median (IQR) 6.0 (4.0–8.5) 6.0 (4.0–9.0)
Baseline
n 146 150
Mean (SD) 6.5 (3.3) 6.4 (3.0)
Median (IQR) 6.0 (4.0–8.0) 6.0 (4.0–8.5)
6 weeks
n 142 137 1.0 (0.3 to 1.8); 0.01
Mean (SD) 4.0 (3.5) 3.0 (3.1)
Median (IQR) 3.0 (1.0–6.0) 2.0 (1.0–5.0)
12 months
n 131 123 0.0 (–0.8 to 0.8); 0.98
Mean (SD) 3.6 (3.2) 3.6 (3.3)
Median (IQR) 3.0 (1.0–5.0) 3.0 (1.0–5.2)
Mean difference is adjusted for age, gender, prior treatment and surgeon.
TABLE 12 Percentage of participants with haemorrhoid symptom severity scores of ‘0’ or ‘1‘
Time point
Treatment group
OR (95% CI); p-valueRBL HAL
Randomisation 2/83 (2%) 4/80 (5%)
Baseline 2/146 (1%) 5/150 (3%)
6 weeks 44/142 (31%) 52/137 (38%) 0.73 (0.44 to 1.22); 0.23
1 year 35/131 (27%) 38/123 (31%) 0.79 (0.46 to 1.38); 0.42
Mean difference is adjusted for age, gender, prior treatment and surgeon.
RESULTS
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FIGURE 6 The EQ-5D-5L. Note that the area of data points is proportional to the number of participants with that
value. Vertical lines represent median and IQR.
TABLE 13 The EQ-5D-5L health utility
Time point
Treatment group
Difference (95% CI); p-valueRBL HAL
Randomisation
n 86 89
Mean (SD) 0.89 (0.16) 0.92 (0.09)
Median (IQR) 0.92 (0.86–1.00) 0.94 (0.88–1.00)
Baseline
n 149 152
Mean (SD) 0.90 (0.12) 0.89 (0.15)
Median (IQR) 0.94 (0.87–1.00) 0.94 (0.87–1.00)
1 day
n 162 141 0.08 (0.04 to 0.13); < 0.001
Mean (SD) 0.84 (0.19) 0.76 (0.22)
Median (IQR) 0.94 (0.87–0.94) 0.82 (0.69–0.90)
7 days
n 157 133 0.08 (0.05 to 0.12); < 0.001
Mean (SD) 0.92 (0.15) 0.83 (0.18)
Median (IQR) 0.94 (0.89–1.00) 0.90 (0.78–0.94)
21 days
n 151 129 –0.01 (–0.04 to 0.02): 0.35
Mean (SD) 0.92 (0.14) 0.93 (0.11)
Median (IQR) 1.00 (0.87–1.00) 0.94 (0.93–1.00)
continued
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Vaizey faecal incontinence score
Vaizey faecal incontinence scores are provided in Table 14 and Figure 7; higher scores indicate more
severe incontinence. No between–group differences were noted in the Vaizey faecal incontinence scores.
An improvement of around 1 unit was noted in both arms at 6 weeks, with a difference between arms of
–0.1 (95% CI –1.3 to 1.0; p = 0.86). The improvement was maintained at 1 year, with a difference of –0.5
(95% CI –1.8 to 0.7; p = 0.38). A summary of these findings is presented in Table 14 and Figure 7.
Pain
Haemorrhoidal pain was assessed by asking the patient to rate his/her pain related to haemorrhoids as of
today and over the last week. Pain today was asked at baseline and again at days 1, 7 and 21, and, finally,
TABLE 13 The EQ-5D-5L health utility (continued )
Time point
Treatment group
Difference (95% CI); p-valueRBL HAL
6 weeks
n 144 137 –0.02 (–0.05 to 0.01): 0.12
Mean (SD) 0.92 (0.13) 0.94 (0.11)
Median (IQR) 0.95 (0.89 to 1.00) 1.00 (0.93 to 1.00)
1 year
N 128 123 –0.02 (–0.06 to 0.03): 0.46
Mean (SD) 0.89 (0.17) 0.91 (0.16)
Median (IQR) 0.94 (0.84 to 1.00) 0.94 (0.87 to 1.00)
Mean difference is adjusted for age, gender, prior treatment and surgeon.
TABLE 14 Vaizey faecal incontinence scores
Time point
Treatment group
Difference (95% CI); p-valueRBL HAL
Randomisation
n 84 88
Mean (SD) 6.0 (5.3) 4.9 (4.6)
Median (IQR) 4.0 (1.0–10.0) 4.0 (2.0–7.5)
Baseline
n 142 147
Mean (SD) 5.9 (5.2) 5.3 (4.8)
Median (IQR) 4.0 (1.0–9.0) 4.0 (2.0–8.0)
6 weeks
n 137 132 –0.1 (–1.3 to 1.0); 0.86
Mean (SD) 4.0 (4.5) 4.1 (4.9)
Median (IQR) 3.0 (0.0–6.0) 3.0 (0.0–6.0)
1 year
n 118 107 –0.5 (–1.8 to 0.7); 0.38
Mean (SD) 4.0 (4.7) 4.5 (4.5)
Median (IQR) 2.0 (0.0–6.0) 3.0 (1.0 –7.0)
Mean difference is adjusted for age, gender, prior treatment and surgeon.
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at 6 weeks. Pain over the last week was asked at days 7 and 21, and, finally, at 6 weeks. Both of these
are summarised in Tables 15 and 16 and Figures 8 and 9; a score of ‘0’ = ’no pain’, whereas a score of
‘10’ = ’worst imaginable pain’. The change in pain as recorded by VAS is shown in Table 17. Pain was
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FIGURE 7 Vaizey faecal incontinence score. Note that the area of data points is proportional to the number of
participants with that value. Vertical lines represent median and IQR.
TABLE 15 Level of pain relating to haemorrhoids: pain experienced today
Time point
Treatment group
Difference (95% CI); p-valueRBL HAL
Randomisation
n 84 89
Mean (SD) 2.4 (2.6) 2.3 (2.5)
Median (IQR) 1.0 (0.0–4.0) 1.0 (0.0–3.3)
Baseline
n 148 150
Mean (SD) 2.2 (2.5) 2.5 (2.7)
Median (IQR) 1.0 (0.0–4.0) 1.0 (0.0–5.0)
1 day
n 162 140 –1.2 (–1.8 to –0.5); < 0.001
Mean (SD) 3.4 (2.8) 4.6 (2.8)
Median (IQR) 3.0 (1.0–5.2) 5.0 (2.0–7.0)
7 days
n 157 133 –1.5 (–2.0 to –1.0); < 0.001
Mean (SD) 1.6 (2.3) 3.1 (2.4)
Median (IQR) 1.0 (0.0–2.0) 3.0 (1.0–5.0)
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TABLE 15 Level of pain relating to haemorrhoids: pain experienced today (continued )
Time point
Treatment group
Difference (95% CI); p-valueRBL HAL
21 days
n 151 129 –0.1 (–0.6 to 0.3); 0.44
Mean (SD) 1.3 (2.0) 1.4 (1.9)
Median (IQR) 0.0 (0.0–2.0) 1.0 (0.0–2.0)
6 weeks
n 144 137 0.2 (–0.2 to 0.7); 0.32
Mean (SD) 1.2 (2.1) 1.0 (1.8)
Median (IQR) 0.0 (0.0–2.0) 0.0 (0.0–1.0)
TABLE 17 Change in VAS pain from baseline
Time point
Treatment group
Difference (95% CI); p-valueRBL HAL
1 day
n 160 136 –1.0 (–1.6 to –0.3); 0.007
Mean (SD) 1.1 (3.1) 2.1 (3.0)
Median (IQR) 1 (0 to 3) 2 (0 to 4)
More painful 90 (56%) 97 (71%)
Same 34 (21%) 18 (13%)
Less painful 36 (23%) 21 (15%)
TABLE 16 Level of pain relating to haemorrhoids: pain experienced over last week
Time point
Treatment group
Difference (95% CI); p-valueRBL HAL
7 days
n 157 133 –2.3 (–3.0 to –1.6); < 0.001
Mean (SD) 3.9 (3.2) 6.3 (2.9)
Median (IQR) 3.0 (1.0–7.0) 7.0 (4.0–9.0)
21 days
n 151 129 –0.3 (–0.9 to 0.4); 0.38
Mean (SD) 2.1 (2.7) 2.4 (2.5)
Median (IQR) 1.0 (0.0–4.0) 2.0 (0.0–3.0)
6 weeks
n 144 137 0.2 (–0.4 to 0.7); 0.56
Mean (SD) 1.7 (2.6) 1.6 (2.3)
Median (IQR) 0.0 (0.0–3.0) 0.0 (0.0–2.0)
Mean difference is adjusted for age, gender, prior treatment and surgeon.
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TABLE 17 Change in VAS pain from baseline (continued )
Time point
Treatment group
Difference (95% CI); p-valueRBL HAL
7 days
n 155 129 –1.4 (–2.1 to –0.7); < 0.0001
Mean (SD) –0.7 (2.9) 0.7 (2.8)
Median (IQR) 0 (–2 to 0) 1 (0 to 2)
More painful 38 (25%) 72 (56%)
Same 48 (31%) 25 (19%)
Less painful 69 (45%) 32 (25%)
21 days
n 149 127 –0.1 (–0.7 to –0.6); 0.880
Mean (SD) –1.0 (2.9) –1.0 (2.8)
Median (IQR) –1 (–2 to 0) 0 (–2 to 0)
More painful 25 (17%) 26 (20%)
Same 49 (33%) 45 (35%)
Less painful 75 (50%) 56 (44%)
6 weeks
n 142 132 0.3 (–0.4 to 0.9); 0.410
Mean (SD) –1.0 (2.9) –1.3 (2.6)
Median (IQR) 0 (–2 to 0) –1 (–3 to 0)
More painful 30 (21%) 16 (12%)
Same 46 (32%) 48 (36%)
Less painful 66 (46%) 68 (51%)
Mean difference is adjusted for age, gender, prior treatment and surgeon.
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FIGURE 8 Visual analogue scale pain scores: pain today.
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increased in the HAL group at one and seven days after the procedure, but the groups were similar at
day 21 and at 6 weeks.
Clinical appearance of haemorrhoids at proctoscopy
Proctoscopy was conducted at the 6-week visit only if the patient reported continuing symptoms;
proctoscopy was conducted more often in the RBL group. The data in Table 18 show that, in the majority
of patients in whom proctoscopy was conducted, the grade had reduced at 6 weeks, with a one-grade
increase observed in only four patients in the RBL group and none in the HAL group.
All important harms or unintended effects in each group
A total of 15 individuals reported SAEs. One patient (in the RBL arm) experienced several episodes of
bleeding following the procedure: further investigations revealed that the patient had a rectal tumour.
This SAE was classified as pre-existing and is not included in Table 19. Of the remaining 14 SAEs,
12 followed HAL and two followed RBL. One of the participants had been randomised to the RBL arm
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FIGURE 9 Visual analogue scale: pain over the last 7 days. Note that the area of data points is proportional to the
number of participants with that value. Vertical lines represent median and IQR.
TABLE 18 Grade of haemorrhoids at 6 weeks and change from baseline
Grade
Treatment group
RBL (n= 48) HAL (n= 27)
At week 6
Grade I 9 12
Grade II 27 12
Grade III 12 3
Change from baseline to 6 weeks
Grade III→ I 5 4
Grade II→ I or III→ II 17 12
Unchanged 25 11
Grade II→ III 4 0
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but was switched over to HAL, but the summaries in Table 19 are based on the treatment actually
received and include all treated participants. All 14 events were expected.
Other complications, which were not classified as ‘serious’, included fissures, which occurred in 3 out of
143 (2%) of the HAL group and 0 out of 150 in the RBL group. There were no cases of fistula formation
or anal stenosis in either group. At 6 weeks, 10 out of 143 (7%) of the HAL group and 10 out of 150
(7%) of the RBL group had evidence of anal skin tags.
Post hoc analyses
Some post hoc analyses have been discussed in previous sections [see Recurrence (primary outcome)
regarding repeat RBL and recurrence, and see Haemorrhoid Symptom Severity Score’ regarding Nyström’s
use of ‘0’ or ‘1’ on the symptoms scale being a signal of cure].
Pre-randomisation questionnaire
As previously mentioned, the baseline was originally measured prior to procedure as opposed to at
randomisation. Following a recommendation from the DMEC, the protocol was subsequently amended to
allow collection at both time points. The rationale for so doing was that self-reported severity may differ
once the allocated treatment is known, thereby introducing an expectation bias. Specifically, participants
randomised to the more intensive HAL surgery may rationalise their planned treatment by reporting higher
levels of pain and discomfort than those randomised to receive RBL. Furthermore, it is possible that
symptoms may change over time, which would also cause imbalance in pre-treatment values, as waiting
time for HAL was longer than for RBL.
The agreement between pre-randomisation and pre-treatment values were therefore investigated among
patients for whom data were available at both time points. The following are presented for each
self-reported measure:
l The Bland–Altman plot for agreement within each treatment arm, together with the overall mean
difference and 95% limits of agreement (also known as a 95% reference interval). The plot is the
difference between pre-treatment and pre-randomisation (i.e. the change between the two) plotted
against the average of the two. The 95% limits of agreement (also known as reference limits) for the
difference were derived based on a normal distribution and quantify how closely the pre-randomisation
and pre-treatment value agree. The average is plotted on the horizontal axis, which allows assessment
of whether or not (dis)agreement varies according to severity.
l The difference between pre-treatment and pre-randomisation values against time elapsed between
the two. The reference limits were the same as those produced for the Bland–Altman plot. Plotting the
difference against elapsed time between the two measures allows an assessment of whether or not
(dis)agreement increases with the time elapsed between the two measurements.
The agreement is displayed visually for each method in Figures 10–13. The difference and 95% limits of
agreement are also summarised in Table 20, along with the difference between the two means and the
ratio of their variances.
TABLE 19 Serious adverse events by classification
SAE
Treatment group
RBL (n= 178) HAL (n= 162)
Any SAE 2 (1%) 12 (7%)
Systemic complication 0 3 (2%)
Urinary retention 0 2 (1%)
Pelvic sepsis 0 1 (< 1%)
Other 2 (1%) 6 (4%)
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FIGURE 11 Agreement of EQ-5D-5L scores at randomisation and pre-procedure. Bland–Altman graphs are given for
(a) HAL and (b) RBL. Difference between the measures in relation to elapsed time between the two is given for (c) HAL
and (d) RBL.
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FIGURE 10 Agreement of haemorrhoid symptom severity scores at randomisation and pre-procedure.
Bland–Altman graphs are given for (a) HAL and (b) RBL. Difference between the measures in relation to elapsed
time between the two is given for (c) HAL and (d) RBL.
TABLE 20 Agreement between self-completed measures of symptoms, incontinence, EQ-5D-5L and pain
pre-randomisation and pre-treatment
Measure
Treatment group, mean difference
(95% agreement limits)
Difference in
means (p-value)
Ratio of variances
(p-value)HAL RBL
Haemorrhoid symptom score 0.0 (–3.0 to 3.0) 0.1 (–3.0 to 3.1) –0.1 (0.823) 0. 96 (0.864)
EQ-5D-5L –0.01 (–0.13 to 0.11) –0.00 (–0.12 to 0.11) –0.01 (0.508) 1.11 (0.691)
Vaizey faecal incontinence score –0.1 (–5.6 to 5.3) 0.4 (–2.7 to 3.5) –0.5 (0.231) 3.14 (< 0.001)
VAS pain 0.2 (–3.8 to 4.2) –0.0 (–2.5 to 2.4) 0.2 (0.479) 2.63 (< 0.001)
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Overall, the extent of agreement was generally similar regardless of the severity. For the VAS pain score,
there was some indication that the pre-randomisation and pre-procedure time points were in closer
agreement in the HAL arm than the RBL arm, as demonstrated by the ratio of the two variances
(2.63; F-test p < 0.001). The same was also true for incontinence, as estimated by the Vaizey tool, where
the difference between randomisation and procedure again tended to be greater in the HAL arm than the
RBL arm (ratio of variances 3.14; p < 0.001). On the other hand, the two values differed less in the HAL arm
for the EQ-5D ‘thermometer’ health state (ratio of variances 0.48; p = 0.004), although this may reflect a
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FIGURE 12 Agreement of Vaizey scores at randomisation and pre-procedure. Bland–Altman graphs are given for
(a) HAL and (b) RBL. Difference between the measures in relation to elapsed time between the two is given for
(c) HAL and (d) RBL.
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FIGURE 13 Agreement of VAS pain scores at randomisation and pre-procedure. Bland–Altman graphs are given for
(a) HAL and (b) RBL. Difference between the measures in relation to elapsed time between the two is given for
(c) HAL and (d) RBL.
DOI: 10.3310/hta20880 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 88
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35
handful of participants with outlying values. There was no indication of any systematic change (i.e. no
consistent deterioration or spontaneous resolution between randomisation and procedure) on any measure.
Haemorrhoidal artery ligation device
Among participants undergoing HAL, the preferred surgical device appeared to be determined by site
rather than participant characteristics. Five sites (n = 73) used the AMI HALO device on all participants,
with the remaining 12 sites using the THD device in 87 cases and the HALO device in two. There was no
significant difference in outcomes between the types of device, although fewer recurrences were seen in
those in the THD arm (26% vs. 35%; adjusted OR 0.65, 95% CI 0.33 to 1.29; p = 0.22). Symptoms and
pain were also similar for the two procedures, data are shown in Table 21. The Vaizey faecal incontinence
score was higher for THD than HALO at 6 weeks (mean scores 5.2 vs. 3.2) and 1 year (means 5.6 vs. 3.5),
but also prior to procedure (means scores 6.3 vs. 4.8). As a consequence, the magnitude of the difference
at 6 weeks (mean difference = 2.0, 95% CI 0.5 to 3.6; p = 0.01) was greater than the change from
baseline (mean difference incorporating an adjustment for baseline = 1.3, 95% CI –0.3 to 2.8; p = 0.11).
TABLE 21 Outcomes for the two HAL devices used in the trial
Measure: time point
Device
THD vs. HALOHALO THD
n (%) with recurrence n (%) with recurrence OR (95% CI); p-value
Recurrence
6 weeks 5 (7) 8 (11) 2.23 (0.57 to 8.76); 0.250
1 year 26 (35) 23 (26) 0.65 (0.33 to 1.29); 0.221
Mean (SD) Mean (SD) Mean difference (95% CI); p-value
Haemorrhoid Symptom Severity Score
6 weeks 2.9 (2.7) 3.1 (3.3) 0.5 (–0.9 to 1.8); 0.493
1 year 3.5 (2.9) 3.8 (3.6) 0.0 (–1.1 to 1.2); 0.945
Pain (VAS)
1 day 4.7 (2.9) 4.7 (2.9) 0.0 (–0.9 to 0.9); 0.957
7 days 3.3 (2.5) 2.9 (2.3) –0.3 (–1.1 to 0.5); 0.415
21 days 1.5 (2.0) 1.4 (1.9) –0.2 (–1.0 to 0.6); 0.586
6 weeks 0.9 (1.6) 1.0 (2.0) 0.1 (–0.5 to 0.8); 0.697
EQ-5D-5L
1 day 0.78 (0.21) 0.73 (0.25) –0.05 (–0.12 to 0.02); 0.131
7 days 0.83 (0.20) 0.83 (0.15) 0.00 (–0.06 to 0.05); 0.996
21 days 0.93 (0.10) 0.92 (0.13) –0.00 (–0.05 to 0.04); 0.889
6 weeks 0.94 (0.13) 0.94 (0.09) 0.00 (–0.04 to 0.05); 0.829
1 year 0.92 (0.16) 0.90 (0.15) –0.02 (–0.07 to 0.04); 0.575
Vaizey faecal incontinence symptom score
6 weeks 3.2 (4.2) 5.2 (5.6) 2.0 (0.5 to 3.6); 0.010
1.3 (–0.3 to 2.8); 0.110a
1 year 3.5 (3.9) 5.6 (5.2) 1.0 (–1.0 to 3.0); 0.304
a Adjusted for baseline: means for THD device pre-procedure were higher than those for the HALO device (6.3 vs. 1.8).
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Chapter 4 Health-economic results
Data completeness
Over the 12 months trial data collection period, data were missing for some participants for three key
parameters used in the CEA: baseline utility, QALYs and total costs. The extent of missing data is
presented in Table 22. The results of our descriptive analyses checks for missing data shows that the
number of missing data is broadly similar across arms. For instance, the percentages of total costs missing
were found to be 44.9% and 46.5% for RBL and HAL, respectively. These assessments were then used to
inform the imputation model.
Costs
The mean total costs and their SD, skewness and CIs are reported descriptively, by group, in Table 23. These
results are based on complete cases only and no imputation was performed at this stage. Similarly, the costs
for each group of itemised resource use are presented in Table 24. The numbers of complete cases used for
estimating the mean costs for each item and their percentages from the total number of participants per
group are also reported. Figures in Table 23 are for complete cases for every category (no missing for all cost
categories), whereas figures in Table 24 are the complete cases within each category. There is limited value
of calculating and interpreting differences in mean costs at the level shown in Table 24 because of missing
data and non-adjustment for patient covariates at this level. The adjusted mean difference in costs for
HAL compared with RBL was estimated using regression analysis and reported within the CUA results
(see Cost–utility analysis results, below). However, Table 24 shows the share of costs between different
items, where the mean cost of further HAL procedure represents the highest share for the RBL group
(£203.76), whereas the mean procedure cost is at the top for the HAL group (£732.56). The cost data are
right-skewed, with only a few patients incurring very high costs in both arms of the trial. The histograms of
cost data distribution for each group are shown in Figures 14 and 15 for RBL and HAL, respectively.
TABLE 22 Data completeness for key parameters used in the CEA
Parameter
Treatment group, missing data: n (%)a
Difference in % missing
All participants
(N= 372): n (%)aRBL (n= 187) HAL (n= 185)
Baseline utility 38 (20.3) 33 (17.8) –2.5 71 (19.1)
QALYs 102 (–54.5) 93 (50.3) –4.3 195 (52.4)
Total cost 84 (44.9) 86 (46.5) 1.6 170 (45.7)
a The percentage shown for each arm is the percentage from the sample randomised to the treatment arm.
TABLE 23 Mean total costs of resource use for complete cases by group (unadjusted)
Treatment group n Mean costs (£) SE Skewness 95% CI
RBL 103 708.67 95.4 2.33 109 to 6000
HAL 99 1766.52 101.5 2.57 776 to 7014
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TABLE 24 Mean costs of resource use for complete cases by group (unadjusted)
Type of resource use
Treatment group
RBL HAL
Mean costs (£) SD n (%) Mean costs (£) SD n (%)
Medications 2.04 8.4 187 (100) 7.59 8.4 185 (100)
RBL procedure 109.00 0.0 187 (100) 0.00 0.0 185 (100)
Excisional tag removal 0.00 0.0 187 (100) 10.02 31.6 185 (100)
HAL procedure 0.00 0.0 179 (96) 732.56 299.7 151 (82)
Admissions for surgery 0.00 0.0 187 (100) 23.01 80.5 158 (85)
Proctoscopy 5.02 5.5 149 (80) 4.71 5.5 140 (76)
Other elective procedure 0.00 0.0 187 (100) 7.23 98.4 185 (100)
Post-discharge admissions 41.73 253.0 150 (80) 65.66 314.9 143 (77)
Other procedures 0.00 0.0 150 (80) 0.76 9.1 143 (77)
Repeated RBL 82.45 276.3 187 (100) 32.05 148.0 185 (100)
Further HAL 203.76 587.6 187 (100) 18.72 179.6 185 (100)
EH 16.14 155.6 187 (100) 24.47 191.1 185 (100)
SH 26.51 255.6 187 (100) 0.00 0.0 185 (100)
RBL in theatre 21.47 218.4 187 (100) 14.47 138.8 185 (100)
Admissions in 1 year 17.78 166.4 176 (94) 68.04 320.1 161 (87)
Emergency procedure 29.53 284.8 187 (100) 29.85 286.3 185 (100)
Consultant visits 88.59 131.2 175 (94) 86.39 151.2 161 (87)
GP visits 10.93 27.8 122 (65) 16.54 35.2 114 (62)
Nurse visits 0.56 6.2 122 (65) 0.85 3.8 113 (61)
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FIGURE 14 Distribution of cost data: RBL.
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Outcomes
We examined the relationship between EQ-5D-5L and the haemorrhoids symptom score in order to
validate the use of EQ-5D-5L as an outcome measure in the economic evaluation. Figure 16 plots the
mean symptom scores and mean EQ-5D-5L utility scores for all participants and visits for both the observed
data, and the fit from a simple linear regression (controlling for age). The plot shows that symptom score is
closely related to EQ-5D-5L, with a unit increase on the 15-point symptom score corresponding to an
approximate 0.02 reduction in the EQ-5D-5L.
0.0008
0.0006
0.0004
0.0002
D
en
si
ty
0.0000
0 2000 4000 6000
Total cost (£)
8000
FIGURE 15 Distribution of cost data: HAL.
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FIGURE 16 Symptom score vs. EQ-5D-5L.
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The mean baseline utility and QALYs for RBL and HAL and mean differences with their SDs and CIs are
reported in Table 25. The trend of EQ-5D-5L score baseline and subsequent follow-up over 12 months’
time horizon (1 day, 1 week, 3 weeks, 6 weeks and 12 months) for both RBL and HAL for complete cases
is shown in Figure 17. The EQ-5D-5L scores for each time points are descriptively reported above [see
European Quality of Life-5 Dimensions (5-level version)].
Cost–utility analysis results
The ICER estimate from our primary analysis, which was based on imputed data, was £104,427 per QALY
gained. The estimated differential costs, and differential QALYs and their SE, p-value and CIs are reported
in Table 26. The mean difference in total cost is £1027 (95% CI £782 to £1272) for the HAL group
compared with RBL (p < 0.001). However, the difference in QALYs – controlling for baseline utility – is very
small (0.01, 95% CI –0.02 to 0.04) and not statistically significant (p = 0.49). The mean total cost of HAL
was £1750 (95% CI £1333 to £2167) compared with £723 (95% CI £551 to £896) for RBL based on
imputed data. The correlation of the residuals in the costs and effectiveness (QALY) equations from the
SUR regression was 0.1063 and not statistically significant (p = 0.246). The full regression results are
provided in Appendix 3.
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FIGURE 17 Mean EQ-5D-5L scores over 12 months’ follow-up.
TABLE 26 Differential cost and differential QALYs based on SUR (HAL vs. RBL)
Outcome Differential mean SE t p-value 95% CI
Costs (£) 1027 124 8.25 < 0.001 782 to 1272
QALYsa 0.01 0.014 0.69 0.489 –0.02 to 0.04
a Controlling for base-line utility as a covariate in the QALY regression equation.
TABLE 25 Descriptive statistics for baseline utility and QALYs
Parameter
Treatment group
Difference
in means t
RBL HAL
n Mean SD Min. Max. n Mean SD Min. Max.
Baseline utility 149 0.90 0.12 0.26 1 152 0.89 0.15 –0.07 1 –0.01 –0.617
QALYs 85 0.91 0.01 0.88 0.93 92 0.91 0.01 0.88 0.94 0.004 0.180
Max., maximum; Min., minimum.
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The CEAC curve generated from the parametric analysis, applied on imputed data, is presented in Figure 18.
This graph shows the probability that the HAL procedure is cost-effective under a range of values for
the cost-effectiveness threshold. At £20,000 per QALY threshold, HAL has zero probability of being
cost-effective; at £30,000 threshold it has 0.05 probability of cost-effectiveness.
The confidence ellipses graph shown in Figure 19 represents the ICER point estimate in the cost-effectiveness
plane, with 50%, 75% and 95% CIs around the point estimate. As can be seen, the ICER point estimate
falls in the north-east quadrant of the cost-effectiveness plane, suggesting that HAL is more costly and more
effective than RBL procedure. However, the incremental QALY is very small and the confidence ellipses cross
the vertical zero line, indicating that we are less confident that incremental QALY is positive.
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FIGURE 19 Cost-effectiveness confidence ellipses illustrating the ICER point estimate and CIs.
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FIGURE 18 Cost-effectiveness acceptability curve showing the probability that HAL is cost-effective given different
values of cost-effectiveness threshold.
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Figure 20 illustrates the incremental net monetary benefit (NMB) line with CI, which shows the same
information around uncertainty in a different way. In this NMB approach, the incremental QALYs were
converted into monetary terms using the upper bound of NICE cost-effectiveness threshold of £30,000 per
QALY. As shown in Figure 20, if the policy-maker is willing to pay £104,427 per QALY gained from
introducing the HAL procedure then the NMB would be zero, with similar degrees of uncertainty around
this estimate to be either a positive or a negative value.
Result of subgroup analysis
Results from the subgroup analysis performed on (1) new patients and (2) patients with recurrence following
RBL are presented in Figure 21. The ICER estimated for the subgroup of patients with recurrence following RBL
before randomisation is higher than for new patients by £156,987. This result suggests that the generated
QALY gains are more costly for patients with recurrence following RBL (before randomisation) than for new
patients. This is mainly driven by a smaller difference in QALYs for patients with recurrence. For patients with
recurrence following RBL, the mean difference in costs was £1091 (95% CI £623 to £1558; p < 0.001).
The mean difference in QALYs was 0.004 (95% CI –0.049 to 0.058; p= 0.870). For new patients, the mean
difference in costs was £1008 (95% CI £729 to £1286; p< 0.001). The mean difference in QALYs was 0.011
(95% CI –0.020 to 0.042); p= 0.479. See Appendix 3 for the full regression results.
Cost-effectiveness results
The incremental cost per recurrence avoided is estimated to be £4882 (95% CI £3628 to £6135). This
result, based on a derived estimate, shows that RBL groups had 87 (49.43%) recurrences compared with 48
(30%) recurrences for HAL groups [for details on clinical effectiveness, see Recurrence (Primary Outcome),
above]. When a sensitivity analysis based on recurrence from the consultants’ questionnaire was completed
for 1-year follow-up, the estimates of recurrence were 45 (25.6%), for the RBL group recurrences compared
with 15 (9.4%) recurrences for HAL group. The incremental cost per recurrence avoided was estimated to
be £6346 (95% CI £4417 to £7975) when recurrence reported by the consultant was considered.
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FIGURE 20 Net monetary benefit line with CIs at different values of cost-effectiveness threshold. Difference in
mean costs = 1027; difference in mean QALYs= 0.01; SE of the mean differential costs = 124; SE of the mean
differential QALYs=0.014; covariance between costs and QALYs = 0.0443.
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Sensitivity analysis
Using the NHS reference cost for the HAL procedure, rather than the microcosting approach, made a
difference of £48,052 per QALY to the base-case ICER estimate. The ICER for this scenario was estimated to
be £152,479 per QALY, compared with £104,427 per QALY as estimated in our base-case analysis. However,
the cost-effectiveness results remained similar: HAL is highly unlikely to be cost-effective at a maximum
threshold of £30,000 per QALY. The results from this sensitivity analysis are presented in Figure 22. The
regression results from this sensitivity analysis show that the mean difference in costs was £1498 (95% CI
£1262 to £1735; p < 0.001). The mean difference in QALYs was 0.01 (95% CI –0.018 to 0.038; p = 0.489).
The full regression results for all sensitivity analyses and model specifications are provided in Appendix 3.
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FIGURE 22 Sensitivity analysis using the NHS reference cost for the HAL procedure.
0.6
(a)
0.4
0.2
Pr
o
b
ab
ili
ty
 t
h
at
 H
A
L 
is
 c
o
st
-e
ff
ec
ti
ve
0
0 30 60 12090
Cost-effectiveness threshold (£000)
ICER = £89,972
0.6
(b)
0.4
0.2
Pr
o
b
ab
ili
ty
 t
h
at
 H
A
L 
is
 c
o
st
-e
ff
ec
ti
ve
0
0 30 60 12090
Cost-effectiveness threshold (£000)
ICER = £246,959
FIGURE 21 Subgroup analysis illustrated by combined CEAC curves.
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Our sensitivity analysis, when controlling for the grade of haemorrhoids, resulted in an ICER of £108,478
per QALY. This result shows the interaction with cost-effectiveness of HAL compared with RBL is
conditional on grade III haemorrhoids. The regression results from this sensitivity analysis show that the
mean difference in costs was £999 (95% CI £760 to £1239; p-value < 0.001). The mean difference in
QALYs was 0.009 (95% CI –0.019 to 0.037; p = 0.518).
The CUA estimates from complete-case analysis using SUR model and controlling for baseline utility are
presented in Table 27. The ICER estimate for this scenario is £90,688 per QALY gained. The correlation
between cost and QALYs based on the Breusch–Pagan test of independence is reported in Table 27:
this shows that cost and QALYs are positively correlated in this study, although this correlation was not
statistically significant.
The results from the sensitivity analysis applying an estimated utility decrement for each subsequent
procedure did not materially change the cost-effectiveness result. From this analysis, the mean difference in
cost was £1030 (95% CI £760 to £1300; p < 0.001). The mean difference in QALYs was 0.008 (95% CI
–0.020 to 0.036; p = 0.562), leading to an ICER of £125,076 per QALY gained. See Appendix 3 for full
regression results.
Long-term cost-effectiveness
Results from the long-term CUA for HAL compared with RBL over a 4-year time horizon generated
incremental costs of £1117 and incremental QALYs of 0.051, leading to an ICER of £21,887. Table 28
shows the deterministic cost-effectiveness result for the long-term extrapolation analysis. This result
indicates that HAL remains not cost-effective at a £20,000 per QALY threshold.
The PSAs resulted in a mean difference in cost of £1125 for HAL compared with RBL, and mean difference in
QALYs of 0.052, and, when combined together, led to an ICER of 21,798 per QALY gained. The probability
of HAL being cost-effective at a £20,000 threshold from the long-term analysis was 0.34. Figure 23 shows
the joint distribution and the uncertainty around costs and QALYs estimated from the extrapolation analyses.
Each point represents a possible ICER estimate, with 1000 points estimated from the PSA simulations. There
are high levels of uncertainty around both costs and QALYs, with QALYs being the most uncertain estimates.
Therefore, the long-term results should be interpreted with caution. This was mainly driven by the quality of
evidence on long-term recurrence, particularly for HAL.
TABLE 27 Sensitivity analysis: CUA for complete-case analysis using SUR and controlling for baseline utility
Outcome Differential mean SE z p-value 95% CI
Costs (£) 1073 190 5.63 < 0.001 700 to 1447
QALYsa 0.01 0.015 0.68 0.495 –0.02 to 0.04
a Controlling for baseline utility as a covariate in the QALY regression equation.
Correlation between costs and QALYs = 0.1063 (p = 0.246).
TABLE 28 Deterministic long-term cost-effectiveness results
Outcome
Treatment group
Mean difference ICER (£)RBL HAL
Costs (£) 1205 2322 1117
QALYs 3.4807 3.5317 0.0510 21,887
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Summary
The main findings from the within-trial CUA suggests that the HAL procedure is highly unlikely to be
cost-effective compared with RBL. In the base-case results, the difference in mean total costs was £1027
higher for HAL than RBL. QALYs were higher for HAL but the difference was very small (0.01), resulting in
an ICER of £104,427 per additional QALY.
The base-case CEA suggests that the incremental cost per recurrence avoided was estimated £4882. In a
sensitivity analysis scenario using the derived recurrence, the incremental cost per recurrence avoided was
estimated to be £6346.
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FIGURE 23 Uncertainties in the mean difference in costs and QALYs from long-term CEA.
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Chapter 5 Discussion
Main findings
Primary outcome: recurrence
Haemorrhoidal disease is a benign condition and, as such, treatment is primarily aimed at addressing the
patient’s symptoms. In the absence of a validated symptom scoring system, we felt that the most
important determinant of treatment success was patient-reported outcome. This was supported by a
robust patient and public involvement (PPI) exercise carried out during the design of the trial. Clinical
experience tells us that the physical appearance of the anal cushions post-haemorrhoid treatment
correlates poorly with patients’ symptoms, meaning that anorectal visualisation is not a reliable surrogate
of success. We therefore used a simple, dichotomised definition of recurrence as described by Shanmugam
et al.6,51 and measured this at 12 months post intervention. Using this patient-reported outcome alone,
there was no difference in recurrence between the groups at 12 months. However, a number of patients
(particularly those who underwent RBL) had undergone a further intervention for haemorrhoid symptoms
within the 12 months, indicating that any symptomatic relief had been achieved only by further corrective
procedures. Classing these patients as recurrence, the rate for HAL was significantly lower than for RBL
(30% vs. 49%; p = 0.001) at 12 months.
The overall level of recurrence following HAL was higher than the pooled rates reported in two systematic
reviews, which were 11%19 and 17.5%.5 However, it should be noted that the recurrence rate among the
constituent studies varied considerably and ranged up to 60%.64 Similarly, reported recurrence rates for
RBL also vary widely in the literature, ranging from 11% to > 50%.6–11 This range can be attributed to
many factors, but the most pertinent is probably the difficulty in defining exactly what constitutes
recurrence. Some studies rely on clinical examination and patient-reported symptoms,22,25,27,51,64 whereas
others rely solely on symptomatology.24,32 When considering symptoms only, some investigators consider a
patient to be recurrence free when they have no perianal symptoms at all, whereas others consider this
simply an improvement. A classic example of variation dependent on definition is provided by one study64
reporting a very high recurrence rate of 60% at 30 months after a HAL procedure. However, the
investigators report that, at the same time point, 86% of patients described a significant improvement
in symptoms.
We adopted the more pragmatic approach6 described above in which the patient’s perception of symptomatic
improvement was combined with the requirement that no further procedures were required in order to
achieve a non-recurrence at 12 months. There were some practical hurdles to overcome when obtaining these
data: a patient may have indicated that he/she was cured but could have forgotten about a consult or further
treatment in the 12-month period since initial surgery, or a patient may have indicated recurrence when the
‘recurrence’ related to a residual skin tag65 or an alternative diagnosis clearly documented by GP or consultant
records. To address these issues, we used a combination of patient-reported assessment with GP and hospital
consultant perception. A decision tree was developed and followed independently by two assessors who were
blinded to the intervention, with consensus reached on any areas of disagreement. This ensured fidelity and
we felt this resulted in the most accurate assessment of true recurrence that was possible.
Other factors that influence the recurrence rate include the duration of follow-up and the pre-treatment
haemorrhoidal grade. We chose to assess recurrence at 12 months because published data suggest that
most HAL and RBL recurrences occur within 1 year.26 Several studies have shown that using HAL for
higher-grade haemorrhoids or significant prolapse adversely affects the recurrence rate;19,37,41,66,67 they also
conclude that HAL is perhaps most effective for grade II and early grade III disease. We therefore limited
our trial to this most clinically relevant patient population. As RBL is also most effective for this stage of
disease, it was chosen as our comparator (see below).
DOI: 10.3310/hta20880 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 88
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
Linked with recurrence is the need for further treatment. This was required in 31% of the RBL group and
15% of the HAL group. Eighteen per cent of the RBL group required a required further banding, the
vast majority needing only one further procedure. It is common practice to repeat banding as part of a
continuum of treatment in some patients with persistent symptoms, and it could be considered that these
patients were actually treatment successes if by the end of the year they were cured or improved.
Given that RBL is a quick, minimally invasive office procedure in comparison with HAL, it seems clinically
relevant and reflective of actual practice to consider it as a ‘course’ of treatment as opposed to a single
intervention. Including these patients as treatment success resulted in a reduction of the recurrence rate
for the RBL arm from 49% to 37.5%, which was not statistically different from the HAL arm.
Secondary outcomes
Recurrence at 6 weeks
When we examined persistent significant symptoms at 6 weeks (i.e. immediate failure of treatment), the
rates were significantly lower than at 1 year in both groups (HAL 9% vs. 30%; RBL 29% vs. 49%); 13 out
of 143 (9%) patients in the HAL group and 44 out of 150 (29%) patients in the RBL group (p < 0.001)
had persistent symptoms at this time point. The large increase in numbers of recurrences, in both groups
after 1 year, suggests significant symptom deterioration. It is not clear when the deterioration ends.
A prolonged follow-up would be relevant to see if further attrition continues, although current data
suggest that most HAL recurrences occur within the year.26
Symptom severity score
Rubber band ligation and HAL both appeared to improve symptoms, with the improvement at 6 weeks
being larger for HAL than RBL. The mean improvements on the 15-point haemorrhoidal symptom severity
questionnaire were 3.4 points for HAL and 2.5 for RBL at 6 weeks, with an adjusted mean difference of
1.0 (95% 0.3 to 1.8; p = 0.01). Patient’s self-assessed reported symptoms remained lower at 1 year, but
the difference between groups was not maintained at this time point.
The improvement after both interventions was more modest than the one reported in the Nyström
study,42 for which a difference of about 6 points was observed in patients who were undergoing both
haemorrhoidectomy and SH. However, in this study the preoperative score was higher than in our study,
reflecting their criteria being grade III or IV haemorrhoids.
Applying Nyström et al.’s42 definition of cure as 0–1 point on the haemorrhoid symptom severity score,
there was no difference between the two interventions at either 6 weeks or 1 year. Indeed it is striking
how few patients reported a 0–1 symptom score despite considering themselves to be cured or improved
according to our primary outcome measure (about one-third from each group). This suggests that many
patients are not concerned with a certain level of persistent symptoms related to haemorrhoids, and may
suggest that symptom severity scores need to take into account further information. This is consistent with
a trial68 from general practice, in France, for which targeted questionnaires were given to all patients who
were attending over a 2.5-day period. Only 2% were seen primarily with anal symptoms but the targeted
questionnaire suggested that 14% had potential haemorrhoidal symptoms. Perhaps a more lenient cut-off
point is required. It should be noted that the design of the trial means that assessment at 1 year did not
take into account the fact that some patients required a repeat procedure to achieve this level of relief.
Health-related quality of life
As mentioned previously, haemorrhoidal disease is a benign condition and, as such, intervention is
essentially aimed at improving QoL, making this is an important indicator of success. This is particularly
pertinent as haemorrhoids can affect a relatively young, professionally active population.
Our results suggest that the majority of patients had an improvement in their QoL above baseline after
intervention but that improvement was the same for both interventions after day 21. Before this date there
was a difference in favour of RBL, probably related to the fact that the HAL procedure was more painful
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and this pain lasted longer. Although no long-term difference was seen between the two groups, it is
important to note that both procedures did result in an improved QoL score. In other words, both
interventions appear worthwhile from a QoL perspective. The alternative management option of simply
reassuring that there is no sinister cause to patients’ symptoms and giving general lifestyle advice (as many
have poor bowel habit) may not be appropriate.69
Continence
A common symptom of haemorrhoidal disease, particularly when prolapse is present, is persistent soiling.
Anal tone maintains continence and the majority of this resting tone comes from the action of the internal
(and some external) sphincter. However, muscle tone alone is insufficient to provide a complete hermetic
seal around the anal canal and there is therefore a contribution from the haemorrhoidal tissue. It follows
that disruption of this tissue in the form of anal prolapse will lead to inefficiencies in this hermetic seal and
leakage of faecal matter. This registers as varying levels of faecal incontinence and soiling.
Our results are consistent with this: at baseline the majority of participants from both groups had either
no incontinence or very mild incontinence. Correction of the prolapse would be expected to result in a
reduction in soiling and hence Vaizey score. This was, indeed, the case, in that there was a small reduction
in the mean score of 1–2 points after both interventions. There was no difference in continence score
between the two interventions.
From the literature, a small proportion of patients has reported incontinence following both procedures.
The mechanism of this worsening incontinence is not clear. Pre-existing sphincter compromise may often
exist with haemorrhoidal disease, particularly prolapse. It may be that, in these patients, the contribution
form the haemorrhoids towards anal tone is essential for continence. Reduction of the haemorrhoidal bulk
unmasks the pre-existing anal sphincter dysfunction. Whatever the reason, the proportion of patients who
deteriorated after intervention was similar in both groups.
Pain
Our data indicate that patients report increased pain following both procedures (56% RBL vs. 71% HAL).
For RBL this pain was usually of low intensity (median VAS score on day 1: 3.0) and resolved rapidly to
below baseline (median VAS score day on 7: 1.0). About 50% of patients required analgesics for the
first few days after treatment. For HAL, the pain was significantly greater, with moderate pain at day 1
(median VAS score: 5.0) and mild pain on day 7 post procedure (median VAS score: 3.0). Pain had
resolved in almost all patients by the 3-week assessment (median VAS score: RBL 0.0 vs. HAL 1.0).
Analgesia was required by the majority after a HAL procedure on a daily basis for the first week but tailed
off, such that at 3 weeks three-quarters of patients had stopped taking medication.
Combining and comparing results from published studies regarding pain following HAL is difficult, as
measures of pain are, by definition, subjective, are often vague and vary significantly in both wording and
outcome. Estimates of the incidence of pain, at least in the first postoperative day, vary from 15% to
18.5%.5,19 No indication is given as to the degree of pain, presumably explaining the inconsistency with
our results, for which significantly more patients experienced at least a degree of discomfort and only 6%
had no pain at all. There are a few RCTs for which VAS scores are utilised in a similar fashion to our trial:
collecting VAS scores on various days after the procedure. One RCT24 comparing HAL with EH showed that
for patients who were undergoing HAL, the mean scores were 5.5 on day 1, 2.5 on day 7, and 0 from day
14 onwards. Another RCT,23 comparing HAL with SH, showed mean VAS scores of 3.1 on day 1, 1.6 on
day 7, and 0.2 on day 21. A third trial,30 comparing THD with SH, showed VAS scores of 2 on day 7, 1 on
day 14, and 0.5 on day 21. All of these trials involved mucopexy. This may be the most painful part of the
procedure. One trial that did not include mucopexy reported a mean VAS score of 5 on day 1, dropping to
a mean of 3 by day 7.32 Summarising these findings suggests most patients have moderate pain in the first
few days after surgery, but that this pain recedes to minimal or no pain by 1–3 weeks. This is consistent
with our results.
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Anal pain is the most common complication after RBL. Mild pain is experienced by at least 25–50% of
patients for the first 48 hours after banding,15,70–74 which is also consistent with our results. The pain may
be reduced by the concomitant use of local anaesthetic.73 This was not routinely performed in our trial
but may have significant clinical advantages as well as influencing the health-economic aspect of the
treatment; about 25% of patients are reluctant to return to work, or to usual activities, on the day of
the procedure17,71,72 and 1% may be hospitalised due to the pain.17
Surgical complications
The incidences of SAEs from both interventions were low (12 in HAL group vs. 2 in RBL group). Two patients
from the RBL group (2%) required hospitalisation (one for severe pain and one for bleeding). This is
particularly relevant as the procedure is usually carried out in the outpatient department, often with minimal
consent. A similar incidence of complications and hospitalisation has been highlighted elsewhere: one
study17 suggested immediate complications occurred in two-thirds of all patients. Most complications were
related to pain, as in our trial, and 1% were hospitalised.
There is a vogue for some hospitals to arrange for the RBL procedure to be carried out in a day case
theatre environment or during a separate, planned outpatient appointment, allowing for a formal consent
process to take place. Day case admission may have avoided the need for hospitalisation in only one
patient in our trial, who was complaining of immediate severe pain post procedure. At the very least,
a formal consent process would have made clear to the patient the potential for these complications.
However, there are significant cost implications.
Septic complications were seen in only one case in our series, but have been described extensively in the
literature.13,75 Sepsis may be local, such as perianal abscess formation, or even retroperitoneal sepsis8,76–78
and Fournier’s gangrene79 described after RBL. Rarely the sepsis can be distant; pyogenic liver abscess
formation80–82 and endocarditis83 have been described after RBL, whereas brain abscess has been described
after HAL.84 This reflects the transient bacteraemia that occurs in a small proportion of patients after
haemorrhoidal procedures.13 None of these rare complications was seen in our series and we do not
recommend the routine use of antibiotic prophylaxis.
We saw significant bleeding (requiring admission with or without transfusion) in two patients (1.2%) after
HAL and one patient (0.6%) after RBL. From the literature, bleeding occurs in around 4–5% of patients after
a HAL procedure,5,19 but only 0.15% of these were significant haemorrhages requiring blood transfusion.5
The incidence of bleeding after RBL is 1–2.8%.3,77 Significant bleeding requiring admission or intervention is
more difficult to analyse, but pooling of the data available suggests an incidence of 0.7%,3,11,14–18 Bleeding
is more common if patients are taking anti-platelet agents, non-steroidal anti-inflammatory drugs (NSAIDs)
or anticoagulants.3 These patients were excluded in our trial.
Urinary retention was seen in only two patients, both in the HAL group. Urinary retention has been
described after both HAL and RBL, with a reported incidence of 0.7% after HAL5 and about 0.3% after
RBL.3,11,14,15,17,18,83 Urinary retention is dependent on the severity of disease and degree of surgery, the
analgesia requirement and pre-existing bladder outlet compromise.85–87 In addition, day case treatment
may reduce the incidence.88 Both cases of urinary retention in our trial had HAL combined with significant
mucopexy (more than five mucopexy sutures).
Other complications of HAL reported in the literature include thrombosis in 1.5–6.7%5,19 and fissure in
0.8–10.3%.5,19 Fissure was seen in 2% of our group. The incidence of thrombosis after RBL is < 1.5%3,14
and fissure occurs in < 0.2%.3,11,14,15,17,18,83 Vasovagal faints have been reported as a common occurrence
after RBL (incidence 15%).17 We saw one case each (0.5%) of perianal haematoma and vasovagal syncope,
all in the RBL group; no fissures were reported following RBL. The low incidence of vasovagal syncope in our
trial remains unexplained.
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Clinical appearance of haemorrhoids at proctoscopy following recurrence
The data on clinical appearance at proctoscopy were limited, as most patients did not have re-examination.
Those who were re-examined tended to be the patients who complained of persistent symptoms. Almost
all of these patients had clinical assessment of unchanged or improved grade of haemorrhoids with only
four (8%) from the RBL group being assessed as worse (increased prolapse, grade II–III piles).
Although increased swelling or haematoma as a result of the RBL intervention may explain the deterioration
in this small group, this appears unlikely 6 weeks after the intervention. The time of day at which the
assessment takes place may have an influence. Assessment later in the day may explain increased
engorgement and therefore size. Another possibility is incorrect assessment at baseline. Grade II
haemorrhoids are sometimes misclassified as grade III.89
Health-care costs and cost-effectiveness
The health-care cost analysis is striking. In the base-case results, HAL is around £1000 more expensive.
As there is little difference in overall HRQoL between the two procedures, the ICER per additional QALY is
very high and significantly exceeds the cost-effectiveness threshold of £20,000–30,000 per QALY. Even if a
difference in recurrence is assumed (and this is not definite – see above), the cost per recurrence avoided is
at least £5000. Essentially, HAL is highly unlikely to be cost-effective in terms of incremental cost per QALY.
Results of the subgroup analysis in patients with recurrence following RBL and new patients were broadly
consistent with the overall population. The interaction effect of the grade of haemorrhoids resulted in an
ICER of £108,478 per additional QALY for HAL conditional on patients with grade III piles.
In all scenarios of sensitivity analyses, the ICER remained > £100,000, indicating the robustness of our
base-case results and suggesting that HAL is highly unlikely to be cost-effective. Extrapolating the CUA
beyond the trial suggested a lower ICER of £21,887 per QALY, and HAL remained not cost-effective at
£20,000 threshold. However, this estimate is highly uncertain because of the scarcity of good-quality
evidence on long-term recurrence and utilities, particularly for HAL.
Additional data on health-care costs from other literature are sparse for this condition. Cost analysis has
been carried out in one trial51 comparing SH with RBL: the cost of RBL was estimated at £252, with the cost
of SH being substantially higher and unlikely to be considered cost-effective at 1 year. However, the authors
did assume that the cost of increased recurrence with RBL would mean that the difference in cost would
fall over a longer time horizon. This may be true for HAL, although the relative low cost of RBL makes this
unlikely. It is probably more cost-effective for patients to return for repeated RBL if recurrence occurs.
Another study55 from the literature reported a trial-based CEA comparing SH with RBL for grade II
symptomatic circumferential haemorrhoids, which is comparable with our study. The study55 found that the
mean cost for SH was £1483 higher than for RBL, and generated a negative difference in QALYs (–0.014),
which was not statistically significant. Interestingly, this study55 found that RBL is associated with higher
recurrence rate than SH, with an estimated incremental cost of £4945 per recurrence avoided. The study55
concluded that SH is highly unlikely to be cost-effective compared with RBL. This conclusion is broadly
similar to our findings based on the HubBLe data and, therefore, HAL is also highly unlikely to be
cost-effective compared with RBL.
Strengths and weaknesses
Generalisability
Among the strengths of this study was the pragmatic, multicentre design using a mix of NHS district
general hospitals and teaching hospitals across the UK, which ensures that the results are generalisable to
all patients seeking treatment for grade II/III haemorrhoids. The number of subjects recruited was such that
there can be considerable confidence in the conclusions drawn from the data.
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Definition of recurrence
The difficulties with definition of recurrence have already been highlighted earlier and clearly alluded to in
the literature.90 We feel that the significant lengths to which we have gone to carefully define recurrence
should be regarded as a strength. Our data provide a clinically meaningful result of the true incidence of
recurrence that is primarily patient reported, but has taken into account clinician-derived data of further
consultations and procedures. Clinician reporting alone is likely to be misleading, but at the same time
must be taken into account when it comes to differentiating the symptoms related to haemorrhoids and
other conditions that may co-exist (skin tags, fissures, etc.) that may lead to a false diagnosis of recurrence.
Changes from baseline data
The original design of our trial incorporated a baseline assessment of symptoms at the date of
randomisation. It became clear soon after the start of the trial that there was a discrepancy between the
two arms of the trial, in that many patients randomised to the RBL group had their procedure almost
immediately after randomisation whereas the HAL group often had to wait a significant period on a
waiting list before surgery could be carried out. It is possible that symptomatology would have changed
during that period. Certainly, deterioration could have occurred, but also improvement. Recognition of the
disease issue and the impending thought of surgery may have resulted in an improved lifestyle, which, in
turn, may have improved symptoms (see above). The issue of surgical waiting time delay has been noted
before in surgical trials,91 with a suggestion that the delay does not definitely alter data. To ensure that
baseline data were collected consistently at a time close to intervention, we recollected the baseline data in
those patients who were randomised to the HAL arm. Interestingly, although individual scores changed
between randomisation and the actual procedure, the population average remained similar, suggesting
that either could have been used as a plausible baseline value.
Justification of eligibility criteria
There are numerous therapies available for treatment of haemorrhoids, ranging from simple conservative
therapies through to outpatient treatment and various surgical options. A consensus is emerging that a
tailored approach is required for treatment of haemorrhoids based on grade.92–94 Early-grade haemorrhoids
can be effectively treated conservatively with diet,95,96 alteration in lifestyle94 and, perhaps, medical
therapy,38,97,98 whereas at the other end of the spectrum, grade IV circumferentially prolapsed piles may
respond only to haemorrhoidectomy or SH. The eTHoS trial99 hopes to provide data concerning the optimal
procedure for the more advanced haemorrhoids.
Our main aim was to assess the effectiveness of HAL in the most clinically relevant scenario and compare
with the most appropriate control. HAL appears to be most effective for treatment of grade II and early
grade III piles92 for which non-surgical treatment is also often utilised. These non-surgical methods include
RBL, injection sclerotherapy, cryotherapy, infrared coagulation, laser therapy and diathermy coagulation.
Of all of these non-surgical procedures, RBL seems to be the best in terms of compliance, long-term
efficacy and side effects.100 Therefore, participants with grade II or early grade III haemorrhoids were
selected as investigation group and RBL was selected as our comparator.
The consensus concerning a tailored approach regarding the treatment of haemorrhoids is difficult to
confirm from the evidence available, as most published meta-analyses involve standard pairwise trials
comparing only two surgical treatments directly rather than all available treatments at once. A novel
method of network analysis published by Simillis et al.101 allows simultaneous comparison of all surgical
treatments. It is unfortunate that this meta-analysis has focused on treatment of only grade III and IV
haemorrhoids. The addition of data from the HubBLe trial to the existing data may allow a similar network
meta-analysis for treatment of earlier-grade haemorrhoids.
Haemorrhoidal grading systems
We used the Goligher grading system for haemorrhoids,102 as it is the most widely used grading system.
This system has been criticised by many, particularly with regard to the definition of grade IV haemorrhoids.
Goligher’s original description of grade IV haemorrhoids102 could include either skin tags or an external
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haemorrhoid component alone or in addition to a mucosal prolapse that needs manual positioning.
There is less ambiguity with regard to grade II haemorrhoids, and grade III haemorrhoids are patient
reported (i.e. the need to manually reduce). However, we have to accept that the definition of early grade III
haemorrhoids has an element of ambiguity. From a pragmatic point of view, the eligibility of a patient for
the trial was decided by the surgeon, who had to decide if the grade III piles were potentially treatable
by the interventions prescribed.
Learning curve
The HAL procedure appears simple and easy to learn, and most investigators have assumed this to be the
case.22,103,104 However, there are no good data on the learning curve and the steps that are required to
achieve competence. The existence of a learning curve has been alluded to. Pucher et al.19 pointed out that
many case series include the particular centre’s initial experience and describe a poorer outcome in the early
patients.66,105 Our trial required that surgeons had to have carried out at least five mentored cases and an
additional five procedures prior to delivering the study intervention. This was based on manufacturers’
recommendations, with no data to indicate that this was adequate to have reached the top of the learning
curve for competence. HAL was performed by a clinician who was accredited for independent practice or
supervised by a consultant in 94% of the cases in the trial, and all procedures were completed by clinicians
who met the above criteria.
If we were to be more robust in our requirement for a satisfactory level of competence we would have
had to assess reproducibility. Possible assessments could include placing the stitch adequately to achieve
absence of the Doppler signal. However, Denoya et al.25 describe the Doppler signal not changing in
almost half of the vessels ligated in their study. Reproducibility could relate to detection of all branches of
the superior haemorrhoidal artery. Ratto et al.106 and Denoya et al.25 identified at least six arteries in all
patients. Six ligations were certainly not carried out in all of our participants. An interesting analysis would
be to see if the number of ligations correlates with the incidence of recurrence.
To add to the difficulties in assessment of reproducibility that is dependent on efficacy of detection and
effective ligation of all branches of the superior haemorrhoidal artery, recent scepticism has focused on the
validity of de-arterialisation. Autopsy data indicate that additional branches of the superior rectal artery
are not detected even with a Doppler probe.107 Two RCTs29,32 have randomised patients to HAL with or
without Doppler probe guidance; both suggested similar results at 1-year follow-up.
Variation in intervention
Haemorrhoidal artery ligation
Haemorrhoidal artery ligation can be carried out using two equipment devices, both utilising the same
principles. We allowed use of both devices within the trial, with sites invariably preferring the same device
on all of their patients. There were no differences in outcomes between the different devices.
Our study included mucopexy as the standard of care. It is widely accepted that this part of the procedure
produces more pain than simple artery ligation. A suture placed too near the dentate line or incorporating
too much rectal tissue can result in increased pain and prolonged recovery. Again, there are few data in
the literature to verify this finding, but some surgeons leave out this part of the procedure; others include
it, as they claim it reduces the recurrence rate. However, data are lacking; only one previous study30 has
compared patients undergoing mucopexy to those with only artery ligation and showed no difference in
end points but numbers were small. An interesting analysis would be to see if the number of mucopexy
ligations correlates with the incidence of recurrence as well as the intensity of pain after surgery.
As alluded to in the learning curve discussion, some trials have suggested that the Doppler part of the
procedure is unnecessary.29,32 This conclusion remains controversial. One of the trials did not include
mucopexy in either procedure arm and had short-term follow-up. Both had relatively low numbers of
participants. Nevertheless, this may be a factor that could significantly reduce costs and should perhaps be
a subject for future research.
DOI: 10.3310/hta20880 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 88
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
Rubber band ligation
There are various potential variations in practice for the procedure of RBL. The procedure was originally
described by Blaisdell108 and modified by Baron using a forceps device.109 More recently, and in the case of
all of our recruiting centres, a suction device is used. Various suction banding devices can be used – some
including a single firing, others delivering multiple bands. One small RCT110 has suggested that suction
banding is superior in terms of pain and bleeding.
Combination of RBL and injection sclerotherapy has been suggested as a more effective method of
treatment than RBL alone,111,112 but remains unproven in a well-designed trial.
The use of concomitant local anaesthetic has already been mentioned in the discussion about pain. Other
variations in practice include the number of bands placed at each haemorrhoidal column. Again, no robust
data exist to suggest that either technique is superior.
Variation between interventions
There was no blinding of participants or site staff in the trial as a result of the HAL procedure requiring
general anaesthetic. Although equipoise was not measured in patients or clinicians, we believe equipoise
was communicated to potential participants, as we produced a video for recruiting staff, highlighting the
issues of randomisation and equipoise in relation to informed consent.
Symptom severity score
At the time of design of this trial, there were no validated scoring systems for haemorrhoids. The nearest we
could come to such a system was that designed by Nyström et al.,42 who altered a validated scoring system
used for assessing colopouch function after rectal resection. The score has allowed a numerical assessment
of the effect of both interventions, and results have complimented the dichotomous primary outcome.
However, the score is not validated. For trials such as this, for which there is a poly-symptomatic condition
and treatment effect must be guided by all of the patient’s symptoms and their respective influence on QoL,
there is a need for a validated score. Subsequent to our study starting, such a score, known as the Sodergren
score, has been developed and validated using a small population of patients.113 Further assessment of
validity is required and data from our trial may allow further development in this area.
Length of follow-up
We chose ‘1 year’ as the time for our primary outcome, as evidence suggests that most recurrences occur
within the first year. However, there is definite evidence of continued recurrences with time for both
procedures3,27 and from our own data, with the striking deterioration seen at 1 year assessment compared
with 6 weeks. For RBL, a further 20% may recur at 3 years, even if repeat RBL is carried out. The numbers
may be similar for HAL.37 The need for a longer-term follow-up for this subgroup is essential for further
information regarding effectiveness and health economics. Modelling to assess ongoing costs and to see if
HAL becomes cost-effective with time is planned but requires at least a further year of data to give more
reliable predicted outcomes.
One other aspect related to follow-up is the issue of repeat banding. Our original protocol did not
incorporate the analysis of HAL compared with repeat banding. The timing of this repeat banding was
therefore not recorded. It is likely that most repeat procedures were carried out at, or soon after, the
6-week follow-up. However, a proportion of these were carried out later. For these patients the
subsequent review at 1 year from the index procedure may not be long enough from the last banding
episode to allow for confidence in the true level of recurrence.
Rubber band ligation as a course of therapy
In retrospect, an alternative design could have been considered in which HAL is compared with a ‘course’
of RBL. Such a course is difficult to define. Is it simply two episodes of RBL? Is it RBL, repeated only if there
has been some response? Is it RBL ad infinitum? Is it RBL until the patient or clinician calls a halt and
alternative procedures are requested? Design of such a trial is simple if the course is defined as two
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episodes of RBL, perhaps 6 weeks apart, with follow-up for 1 year after the last RBL. Designing a trial to
evaluate alternative treatment strategies is difficult. The current study has allowed the post hoc analysis of
repeat RBL to be assessed while maintaining a feasible and pragmatic design.
Meaning of the study and implications for clinicians or policy-makers
Haemorrhoidal artery ligation is a more invasive procedure than RBL, requiring admission to hospital,
longer waiting times, an anaesthetic and a more prolonged recovery. When offered an intervention for
haemorrhoids, most patients would choose a more invasive procedure only if it were significantly more
likely to achieve cure. Our data suggest that higher cure is true; the recurrence rate after HAL is
significantly less than RBL and symptoms are more likely to be reduced. However, the recurrence rate
for both procedures is high and may be considered by many patients as too high. Our data suggest that
the HAL procedure in particular is not as effective as the current literature indicates. Similarly, recurrence
after one episode of RBL is very likely. Many patients will undergo further interventions within the year and
over one-quarter will still not consider themselves improved or cured. Given this level of recurrence,
alternative procedures may be appropriate. However, a vigorous assessment of efficacy similar to this trial
would be required in order to fairly compare these alternatives, be they conservative therapy or surgical
intervention. The eTHoS trial99 may provide this information for SH and haemorrhoidectomy.
Waiting times deserve an additional comment. It takes substantially longer for a HAL procedure to be
carried out. Although not recorded, during the period of waiting for a HAL, patients will continue with
symptoms whilst a large proportion of those in the RBL group would have had relief and improved QoL.
Despite this gloomy primary outcome data, it is important to state that symptom severity score, continence
score and QoL improved after both interventions, suggesting that both interventions are beneficial to patients.
Would most patients who accept an intervention therefore choose HAL as it is the most effective procedure?
The patient representative for the trial does not think that HAL appears to be the most effective procedure,
and would opt for HAL only if it had much lower recurrence. Patients are likely to be influenced by other
secondary factors, such as complications and QoL. Neither of these outcomes was different between
interventions. Short-term pain was significantly higher in the HAL group, although the pain suffered after
intervention tended to be mild to moderate and resolved within 1–3 weeks. Our trial also showed that
many patients had to wait longer for a HAL, with most receiving RBL on the day of consult. Furthermore,
of the screened patients who did not enter the trial, 128 opted for the RBL procedure and 70 for the HAL
procedure. Given these factors, it could be argued that many patients would choose RBL, over HAL, as they
would be inclined to ‘take their chances’ with a simple and quick outpatient procedure, without general
anaesthetic, returning for a repeat procedure after a few months to years if recurrence occurred. A repeat
RBL would be a simple and palatable option. Indeed many clinicians would consider RBL to consist of a
‘course’ of treatment rather than a single procedure, illustrated by the fact that it is common practice for
many patients to be routinely followed up some weeks later, when repeat banding can easily be carried
out. If those requiring repeat RBL to achieve control at 1 year are included as treatment successes then the
difference between the two groups becomes insignificant.
Of course there is another factor that may influence the patient choice of HAL over RBL, and that is the
long-term incidence of recurrence. Very few long-term data exist for RBL but the data that are available
suggest a significant deterioration with time.3 Some long-term trials on HAL also suggest significant
attrition.37 All trials on long-term data have significant methodological issues as well as significant
ambiguity regarding the definition of recurrence. Our own data suggest significant deterioration in both
groups over the year. It remains to be seen whether this attrition persists. HAL also appeared to improve
symptoms more rapidly than RBL, although this is somewhat offset in practice by the aforementioned
differential waiting time: RBL is a straightforward procedure that was usually done on the same day as
randomisation, whereas the median waiting time for HAL was 60 days.
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One further finding in our trial that has implications for both clinicians, and possibly commissioners, is the
fact that two patients were hospitalised with complications after RBL. RBL is a procedure that is often
carried out in the outpatient department at the time of initial consult: 20% of our recruiting centres follow
this policy. Therefore, there is potentially no formal consent process and potentially inadequate immediate
follow-up as the patient is usually discharged from the department. Some recruiting centres delay RBL,
inviting the patient back to a formal day case theatre setting allowing for adequate informed consent and
monitoring of potential complications. This would appear to be best practice, but does incur increased
management costs.
Finally, it should be noted that there are massive cost implications for the HAL in these patients. RBL is
relatively cheap, even if the patient returns to a day case setting for repeat banding.
Recommendations for future research
This trial adds to the growing body of evidence that proposes various surgical interventions for grade II
and II haemorrhoids. Between them, the HubBLe and eTHoS trials include the four principle treatments
that are used in this patient population: RBL, HAL, SH and EH. Pooling of these data sets with other data
sets that are already available101 may provide the opportunity to conduct an individual patient data (IPD)
meta-analysis (network meta-analysis) to allow a comparison of all four interventions and will allow
surgeons to tailor treatment options to the needs of individual patients. Considering the significant disease
burden of haemorrhoids, this has the potential to provide powerful results. Further to this, a model-based
economic evaluation should be conducted, synthesising all of the available evidence.
We have discussed the difficulties in defining recurrence in haemorrhoidal disease and the lack of a
validated scoring system. The wealth of data available from this trial can now be analysed to enable
such a system to be proposed and validated. This will provide future investigators with a robust and
standardised tool with which to compare treatments and allow comparison between studies.
Our data have demonstrated that recurrence may increase with time. Further follow-up of the patient
cohort would add to the results available regarding long-term effectiveness and allow an updated
economic analysis. We feel that data collection at 2 and 3 years post intervention would provide clinically
relevant information to aid surgeons and patients in treatment selection.
Other possible analyses of these data include correlation of the incidence of recurrence and the number of
arterial branches ligated, as well as the number of mucopexy sutures. In addition, correlation with the
degree of mucopexy and the intensity of pain would be helpful for clinical prediction of outcome.
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Chapter 6 Conclusions
Haemorrhoidal artery ligation is a more clinically effective procedure than a single RBL intervention.However, if HAL is compared with repeat RBL then the procedures become equivalent in terms of
recurrence. Similarly, symptom severity score, complications, QoL and continence score were no different
between interventions, and patients had more pain in the early postoperative period after a HAL
procedure. The HAL procedure is significantly more expensive than RBL and not cost-effective in terms of
cost per QALY.
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Appendix 1 Changes to protocol
Changes to protocol Progress report Date Approved by
Protocol version 2.0: adverse events were
clarified in the protocol and participant
information sheet
1 (1 December 2012) 30 July 2012 NRES Committee
Yorkshire & The Humber –
South Yorkshire
Protocol version 3.0: clarified serious adverse
event reporting to state that only related
adverse events and serious adverse events will
be reported
1 (1 December 2012) 30 August 2012
Protocol version 4.0: a change was made to
the eligibility criteria to exclude patients with
hypercoagulability disorders (in addition to
those on warfarin or clopidogrel)
1 (1 December 2012) 24 October 2012
Protocol version 5.0: the baseline data
collection was changed to the day of surgery,
rather than at randomisation
2 (1 June 2013) 7 February 2013
Protocol version 6.0: the inclusion criteria
‘Either presenting for the first time or after
one failure of RBL’ was replaced by three
exclusion criteria for clarification:
Patients that have had previous surgery
for haemorrhoids (at any time); patients
that have had more than one injection
treatment for haemorrhoids in the past
3 years; and patients that have had more
than one RBL procedure in the past
3 years
2 (1 June 2013) 25 March 2013
Protocol version 7.0: the sentence ‘patients
will have at least 24 hours to decide whether
to take part’ was added to the protocol, to
provide clarification
2 (1 June 2013) 30 April 2013
Protocol version 8.0: a pre-randomisation
questionnaire was added to the data collection
schedule for participants
3 (1 December 2013) 5 July 2013
NRES, National Research Ethics Service.
DOI: 10.3310/hta20880 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 88
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brown et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
71

Appendix 2 Data collection tools
Screening assessment
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Pre-randomisation questionnaire
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Participant questionnaire: 1 year
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Consultant questionnaire: 1 year
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GP questionnaire: 1 year
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Serious adverse event form
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Study completion/discontinuation
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Appendix 3 Health-economic analyses: full
regression results
Base–case analysis: seemingly unrelated regression: imputed data
Model Specification:  
xi: mi estimate, cmdok: sureg (cost i.treat)(QALYs i.treat u_baseline) 
 
Full regression results:  
Multiple-imputation estimates                     Imputations     =         53 
                                                  Number of obs   =        372 
                                                  Average RVI     =     0.7246 
                                                  Largest FMI     =     0.4113 
DF adjustment:   Large sample                     DF:     min     =     313.07 
                                                          avg     =     371.20 
                                                          max     =     438.85 
------------------------------------------------------------------------------ 
             |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
cost         | 
   _Itreat_1 |   1026.946   124.4181     8.25   0.000      782.412    1271.479 
       _cons |   723.1797   87.66625     8.25   0.000     550.8818    895.4776 
-------------+---------------------------------------------------------------- 
QALYs        | 
   _Itreat_1 |   .0098341   .0141964     0.69   0.489     -.018087    .0377552 
  u_baseline |   .3306803    .053144     6.22   0.000     .2261226     .435238 
       _cons |    .620022   .0492367    12.59   0.000     .5231453    .7168987 
------------------------------------------------------------------------------ 
Subgroup analysis: recurrence following rubber band ligation
Model Specification:  
 
xi: mi estimate, cmdok: sureg (cost i.treat)(QALYs i.treat u_baseline) if 
rec_rbl==1 
 
Full regression results:  
Multiple-imputation estimates                     Imputations     =         53 
                                                  Number of obs   =         77 
                                                  Average RVI     =     0.5476 
                                                  Largest FMI     =     0.3751 
DF adjustment:   Large sample                     DF:     min     =     376.16 
                                                          avg     =     478.60 
                                                          max     =     529.11 
 
------------------------------------------------------------------------------ 
             |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
cost         | 
   _Itreat_1 |   1090.589    237.903     4.58   0.000     623.2357    1557.943 
       _cons |   665.4697   157.6587     4.22   0.000     355.6765    975.2629 
-------------+---------------------------------------------------------------- 
QALYs        | 
   _Itreat_1 |   .0044161   .0270361     0.16   0.870    -.0487448    .0575769 
  u_baseline |   .3230415   .1207478     2.68   0.008     .0858376    .5602455 
       _cons |   .6282022   .1098891     5.72   0.000     .4122839    .8441206 
------------------------------------------------------------------------------ 
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Subgroup analysis: new patients
Model Specification:  
xi: mi estimate, cmdok: sureg (cost i.treat)(QALYs i.treat u_baseline) if 
rec_rbl==0 
 
Full regression results:  
 
Multiple-imputation estimates                     Imputations     =         53 
                                                  Number of obs   =        295 
                                                  Average RVI     =     0.6379 
                                                  Largest FMI     =     0.4042 
DF adjustment:   Large sample                     DF:     min     =     324.14 
                                                          avg     =     432.26 
                                                          max     =     559.93 
 
------------------------------------------------------------------------------ 
             |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
cost         | 
   _Itreat_1 |   1007.901   141.7449     7.11   0.000     729.3875    1286.414 
       _cons |   740.9366   100.0157     7.41   0.000     544.4848    937.3884 
-------------+---------------------------------------------------------------- 
QALYs        | 
   _Itreat_1 |   .0112024   .0158279     0.71   0.479    -.0199017    .0423064 
  u_baseline |   .3329039   .0583516     5.71   0.000     .2181083    .4476996 
       _cons |   .6175611   .0540217    11.43   0.000     .5112966    .7238256 
------------------------------------------------------------------------------ 
Sensitivity analysis: using the NHS reference cost for the
haemorrhoidal artery ligation procedure rather than
the microcosting approach
Model Specification: 
xi: mi estimate, cmdok: sureg (cost i.treat)(QALYs i.treat u_baseline) 
Full regression results:  
 
Multiple-imputation estimates                     Imputations     =         53 
                                                  Number of obs   =        372 
                                                  Average RVI     =     0.7213 
                                                  Largest FMI     =     0.4138 
DF adjustment:   Large sample                     DF:     min     =     309.28 
                                                          avg     =     334.93 
                                                          max     =     373.45 
 
------------------------------------------------------------------------------ 
             |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
cost         | 
   _Itreat_1 |   1498.334   120.0387    12.48   0.000     1262.138     1734.53 
       _cons |   622.6863   82.12316     7.58   0.000     461.2045    784.1681 
-------------+---------------------------------------------------------------- 
QALYs        | 
   _Itreat_1 |   .0098265   .0141951     0.69   0.489     -.018092     .037745 
  u_baseline |   .3301776   .0530124     6.23   0.000     .2258849    .4344703 
       _cons |   .6204764    .049095    12.64   0.000     .5238852    .7170676 
------------------------------------------------------------------------------ 
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Sensitivity analysis: controlling for the grade of haemorrhoids
Model Specification: 
xi: mi estimate, cmdok: sureg (cost i.treat heam_grade)(QALYs i.treat u_baseline 
heam_grade) 
 
Full regression results:  
 
Multiple-imputation estimates                     Imputations     =         53 
                                                  Number of obs   =        372 
                                                  Average RVI     =     0.6956 
                                                  Largest FMI     =     0.4089 
DF adjustment:   Large sample                     DF:     min     =     316.70 
                                                          avg     =     363.87 
                                                          max     =     464.18 
 
------------------------------------------------------------------------------ 
             |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
cost         | 
   _Itreat_1 |   999.2027   121.8697     8.20   0.000     759.7181    1238.687 
  heam_grade |    345.978   129.9347     2.66   0.008     90.41559    601.5405 
       _cons |  -91.80375   317.6338    -0.29   0.773    -716.4896    532.8821 
-------------+---------------------------------------------------------------- 
QALYs        | 
   _Itreat_1 |   .0092111   .0142437     0.65   0.518    -.0188038    .0372259 
  u_baseline |   .3306597   .0531358     6.22   0.000     .2261159    .4352036 
  heam_grade |   .0078487   .0143074     0.55   0.584    -.0202813    .0359786 
       _cons |   .6015382   .0594298    10.12   0.000     .4846319    .7184445 
------------------------------------------------------------------------------ 
Sensitivity analysis: complete-case analysis
Model Specification: 
sureg (cost i.treat)(QALYs i.treat u_baseline), corr 
 
Full regression results:  
Seemingly unrelated regression 
---------------------------------------------------------------------- 
Equation          Obs  Parms        RMSE    "R-sq"       chi2        P 
---------------------------------------------------------------------- 
cost              119      1    1037.993    0.2106      31.75   0.0000 
QALYs             119      2    .0827048    0.6377     214.53   0.0000 
---------------------------------------------------------------------- 
 
------------------------------------------------------------------------------ 
             |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
cost         | 
       treat | 
        HAL  |   1073.279   190.4736     5.63   0.000     699.9581    1446.601 
       _cons |   602.2028   137.4856     4.38   0.000      332.736    871.6696 
-------------+---------------------------------------------------------------- 
QALYs        | 
       treat | 
        HAL  |   .0103446   .0151768     0.68   0.495    -.0194014    .0400906 
  u_baseline |   .7807911   .0533427    14.64   0.000     .6762414    .8853408 
       _cons |   .2070643    .049401     4.19   0.000     .1102401    .3038885 
------------------------------------------------------------------------------ 
 
Correlation matrix of residuals: 
 
         cost   QALYs 
 cost  1.0000 
QALYs  0.1063  1.0000 
 
Breusch-Pagan test of independence: chi2(1) =     1.346, Pr = 0.2460 
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Sensitivity analysis: applying utility decrements for each
subsequent procedure
Model Specification: 
xi: mi estimate, cmdok: sureg (cost i.treat)(QALY2 i.treat u_baseline) 
 
Full regression results:  
 
Multiple-imputation estimates                     Imputations     =         53 
                                                  Number of obs   =        372 
                                                  Average RVI     =     0.6984 
                                                  Largest FMI     =     0.4574 
DF adjustment:   Large sample                     DF:     min     =     253.21 
                                                          avg     =     342.82 
                                                          max     =     400.81 
 
------------------------------------------------------------------------------ 
             |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
cost         | 
   _Itreat_1 |   1030.148   137.0264     7.52   0.000     760.2918    1300.005 
       _cons |   727.0494   93.02419     7.82   0.000     544.0094    910.0894 
-------------+---------------------------------------------------------------- 
QALY2        | 
   _Itreat_1 |   .0082362   .0141725     0.58   0.562    -.0196371    .0361094 
  u_baseline |    .330629   .0512231     6.45   0.000     .2299294    .4313285 
       _cons |   .6200022   .0473644    13.09   0.000     .5268864    .7131181 
------------------------------------------------------------------------------ 
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